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Neonatal Abstinence Syndrome (NAS), either as a result of in utero opiate 
exposure or medical exposure in the intensive care unit, carries morbidity for neonates. 
There is no definitive research regarding optimal care for these infants. Thus, optimal 
medications, most effective dosing and strategies for mitigation of long-term 
developmental issues are unknown. In utero opiate exposure leads to chronic neuronal 
changes in opiate receptor signaling and the derangement of these pathways underlies the 
physical manifestations of NAS. Medical opiate exposure, as opposed to in utero 
exposure, involves high doses for shorter periods of time, but the resultant NAS is similar 
in manifestation and treatment. The introduction reviews the most current research on 
opiate tolerance and dependence mechanisms. 
Understanding prescribing patterns of pain and sedation medications in the ICU 
sheds light on NAS risk. Chapter I describes a cohort study quantifying the cumulative 
medical opiate exposure in high risk neonates. Opiate exposure has significantly 
increased over a decade, and this new knowledge may lead to more scrutiny of pain 
protocols, more diligent use of pain scores and opiate weaning protocols to standardize 
pain and sedation treatment in the NICU. 
In utero acquired NAS is treated with replacement opiate when symptoms are 
uncontrolled with non-pharmacologic interventions.  In part due to a lack of 
pharmacologic research in these infants, there currently are multiple empiric morphine 
dosing regimens for NAS leading to widely different lengths of treatment and cost of care 
iii 
 
between institutions. There is no clear understanding of how dose correlates with 
exposure and how exposure correlates with clinical outcomes. Chapter II describes a 
pharmacokinetic (PK) study in infants with NAS, quantifying bioavailability of enteral 
morphine and internally validating models for use in future studies. 
Medicine is undergoing a paradigm shift away from blanket clinical approaches to 
individualized medicine. Maternal opiate maintenance therapy and resultant NAS must 
not be left behind. Chapter III reviews the potential for pharmacogenetics to vastly 
increase our understanding of opiate transfer across the placenta. The goals of my 
research program are to individualize maternal opiate medication choice and dosing, 
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Opiate medications are a critical part of medical care. Opiates are used in the neonatal 
ICU to provide analgesia and sedation to sick patients and opiates are used during pregnancy to 
treat dependent mothers in an effort to prevent fetal withdrawal. The mechanism of action of 
these drugs is well understood on the cellular level, but there is much to be desired regarding our 
understanding of their clinical use in specific populations, including neonates. In this 
introduction, we will review some of the general cellular physiology behind opiate therapy and 
the current leading theories behind the mechanisms of tolerance and withdrawal.  
Pain Physiology and Opiate Receptors  
The pain pathway involves both the peripheral and central nervous system. A peripheral 
pain signal starts with somatic nociceptors which respond to a noxious insult or tissue injury in 
organs such as the skin, muscle, visceral organs or bone. The afferent nerves in the periphery 
transduce the stimulus into impulses which travel along the faster A-delta fibers and then the 
slower C fibers. Certain afferent neurons respond specifically to inflammatory mediators. The 
afferent neurons converge in the dorsal root ganglion near the spinal cord. In the spinal cord, the 
pain signal is modulated and transmitted to higher central nervous system (CNS) levels via the 
spinothalamic tract through the thalamus to the somatosensory cortex. 
 This traditional understanding of the pain pathway is currently under scrutiny as there is 
increasing evidence that other very complex CNS interactions involving the stress response and 
autonomic system also play a distinct role on pain signaling. The parieto-insular cortex is 
important for pain processing. Distinct lamina I cell signaling pathways have been discerned 
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through advanced imaging. These newly described pathways are thought to relay certain types of 
pain messages including sharp, burning and cold.  
Knowledge of the pain pathways gives rise to potential therapeutic drug targets. Binding 
of agonists to the opiate receptors on the presynaptic terminals of peripheral nociceptors leads to 
inhibition of ion channels and decreases the release of pain neurotransmitters. Binding of agonists 
to the opiate receptors on the dorsal root ganglia in the spinal cord leads to inhibition of neuronal 
firing and neurotransmitter release, modulating the transmission of pain signals through the 
spinothalamic tract. In addition, there are opiate receptors in the thalamus and somatosensory 
cortex. These more central opiate receptors are thought to lead to the unwanted side effects of 
opiate therapy including tolerance and dependence.   
Four opiate receptor sub-types have been described, including Mu, Kappa, Delta and 
Nociceptin. Mu opioid receptors (MOR) are found on the peripheral processes of dorsal root 
ganglia neurons, and centrally in the brainstem and medial thalamus. Mu1 type receptors are 
responsible for analgesia while Mu2 type receptors are responsible for respiratory depression, 
pruritis and sedation. Kappa opiate receptors (KOR) are found in the limbic system, the brain 
stem and spinal cord and are thought to play a role in dependence and dysphoria. Delta receptors 
are largely isolated to the brain and their role in pain physiology is not well understood, although 
their potential role in tolerance and withdrawal will be discussed below. Nociceptin opiate 
receptors have been identified in brain tissue but their current contribution to opiate physiology is 
not well understood. 
Current Theories of Opiate Tolerance and Dependence 
Tolerance, physical dependence and subsequent withdrawal are phenomena which 
develop as adaptations to prolonged opiate receptor activation. Tolerance is a change in threshold 
drug dose or concentration needed to achieve the same sedative or analgesic effect, with the need 
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Figure 1: G-Protein Coupled Receptor 
                    www.quizlet.com 
for increased doses over time to achieve the same clinical endpoint. In a study of escalation of 
opiate doses to achieve pain control, adult patients required up to a 10-fold dose increase in dose 
over a 15 month time frame, with younger adults needing a more rapid increase in dose1. 
Withdrawal is the manifestation of physical dependence once the opiate is weaned from the 
system and plays a role in addiction behaviors in adults. Physical dependence is distinct from 
psychological addiction, with specific regard to neonates who cannot manifest the typical drug 
seeking behaviors and functional life disturbances classic of addicted adults. The adaptive 
changes of tolerance and dependence can take place on different levels ranging from protein 
receptor to intracellular pathways to neuronal network connectivity. 
Receptor Physiology  
All four opiate receptors have 
7-transmembrane spanning proteins. 
The opiate receptors are G- protein 
coupled receptors (GPCRs) and their 
activation leads to a series of 
conformational changes and downstream 
intracellular effects.  There are important nuances to 
the simple GPCR paradigm which might influence the propensity for a drug to cause tolerance 
and withdrawal. For example, the opiate receptors are stabilized in different conformations by 
agonists, inverse agonists and neutral antagonists2. These different receptor conformations could 
very well lead to varying downstream signaling cascades3,4.      
Once bound by an opiate receptor agonist, the subunits of the G-Protein dissociate and 
each alpha, beta, and gamma units can lead to downstream cellular changes5.  The main cellular 
changes associated with opiate receptor signaling include alterations in adenylyl cyclase activity 
and intracellular cAMP concentrations and downstream modulation of both potassium and 
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calcium ion channels. Both the up-regulation of potassium influx through the plasma membrane 
leading to overall hyperpolarization of the neuron and the decrease of calcium influx leads to 
decreased neurotransmitter release. 
Through a series of experiments using selective ADP-ribosylation of subunits of the 
inhibitory G-Protein, it was found that one of the intracellular signaling mechanism of opiate 
receptor activation is down-regulation of adenylyl cyclase (AC) activity by the G-alpha subunit6.  
AC inhibition remains the agonist effect most used in research to study the opiate receptors and 
ligand properties. The second important aspect of opiate signaling is the downstream modulation 
of calcium and potassium channels. Following receptor activation and G-Protein dissociation, the 
alpha subunit goes on to directly interact with Kir3, the inward rectifying potassium channel. This 
interaction leads to increased potassium influx and inhibition of tonic neural activity. This was 
shown in experiments using Kir3 knock-out mice, in whom enkephalin (an endogenous opioid 
agonist)-induced hyperpolarization was significantly reduced7. Opiate receptor mediated 
modulation of calcium currents works via binding of the dissociated beta-gamma subunit of the 
G-protein directly to the calcium channel. In a comprehensive review by Tedford et al, the 
discovery history of this calcium modulating activity of GPCR and the many details determining 
the degree of calcium inhibition, including calcium channel alpha-subunit and G-Protein 
structural subunits are reviewed8. 
The remainder of this discussion around tolerance and dependence will focus on 
morphine and the MOR, as morphine is a very widely used analgesic in the neonatal population 
and is also the drug of interest in the pharmacology research undertaken as part of this thesis 
project. 
Mechanisms of Morphine Tolerance and Dependence  
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Mu opioid receptors show basal constitutive activity in cell lines, and their basal activity 
is increased after chronic morphine exposure9.  This increase in basal activity is thought to 
happen via receptor phosphorylation, as protein kinase inhibitors can prevent the transition in 
constitutive activity induced by morphine exposure. In addition to protein kinases, other proteins 
such as calmodulin have been studied for their effect of receptor function. When the MOR is 
unbound, calmodulin binds and competes for binding with the G-protein, preventing basal 
activity. Studies show that after prolonged morphine exposure, calmodulin is released even from 
unbound receptors, leading to ligand-independent receptor activity10. 
In addition to increased basal activity, three other main mechanisms of tolerance have 
been proposed including receptor desensitization, receptor endocytosis and receptor 
downregulation. Desensitization is any process which unlinks the opioid receptor from its G-
Protein mediator or other typically modulated intracellular cascade messenger systems. 
Endocytosis is the process in which the receptor if taken from the plasma membrane into an 
intracellular compartment, making it inaccessible to ligand binding. Downregulation can be 
defined as any decrease in the number of active ligand binding sites, and mechanisms of 
downregulation include receptor degradation and decreased receptor protein transcription. 
Early theories of opioid tolerance revolved mainly around downregulation of opiate 
receptors. Recent evidence suggests that different agonists have differing cellular effects and that 
a more nuanced explanation involving mechanisms such as desensitization and decoupling from 
downstream effect may be more physiologically relevant.  
Desensitization 
An example of desensitization is when the activation of the opiate receptor no longer 
produces the expected cellular events and this can be due to alterations in second messenger 
density or activity, or due to receptor modifications. The first and most rapid form of 
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desensitization involves receptor phosphorylation. G-Protein-coupled receptors kinases (GRKs) 
can phosphorylate the MOR and lead to recruitment of beta-arrestin, uncoupling the MOR from 
the G-Protein and inhibiting transmission of downstream signal. In neurons from the peri-
acqueductal grey area in beta-arrestin knockout mice, tolerance (as measured by uncoupling of 
receptor activation and resultant calcium currents) was reduced following chronic morphine 
exposure when compared to neurons from control mice11. 
A second example of desensitization is alterations in second messenger signaling systems 
leading to a change in the typical cellular response to opiate agonist. Upregulation of proteins 
involved in opiate intracellular signaling pathways such as adenylyl cyclase, protein kinase A 
(PKA) and cAMP response element binding protein (CREB) have all been shown to occur after 
chronic opiate exposure.  Chronic (5 day) morphine administration to rats led to an increase in 
basal and GTP-stimulated adenylyl cyclase in the locus ceruleus, and this effect was not observed 
with shorter morphine exposures of 2 hours and 1 day12. Studies have shown that increased 
adenylyl cyclase activity is isozyme specific13, with some AC enzymes upregulated and some 
downregulated after morphine exposure, further elucidating the complexity of intracellular 
alterations with chronic opiate exposure. In a study of mice using anti-sense message directed at 
PKA mRNA, it was shown that the tolerance induced by chronic morphine infusion could be 
diminished, presumably through inhibition of the transcriptional upregulation of PKA, 
independent of receptor-downregulation14. Acute morphine exposure leads to decreased 
phosphorylation of CREB, which is a transcription factor that mediates the effects of cAMP on 
gene expression. This effect is lost with chronic morphine exposure, and CREB is 
hyperphosphorylated during precipitated opiate withdrawal, suggesting that epigenetic changes to 






Another theory in the development of opiate tolerance involves the “protective effect” of 
agonist-induced endocytosis. Opiate receptor endocytosis was potentially originally designed to 
regulate the physiologic effects of endogenous opioid agonists such as enkephalin and 
endomorphin. The internalization and recycling to the cell surface of opiate receptors is in line 
with physiologic neurotransmitter release which is typically phasic or pulsatile. A hallmark of 
morphine activation of the MOR is that the typical cycle of endocytosis of broken, and this 
change if receptor physiology with exogenous opiate exposure has been linked to the 
development of tolerance. 
When an agonist binds the MOR, the receptor is typically phophorylated by the G-Protein 
coupled receptor kinase (GRK), leading to arrestin recruitment. Arrestin recruitment leads to 
uncoupling of the MOR from the G-Protein, rendering it non-functional and manifesting as 
desensitization. In addition, arrestin-bound G-protein uncoupled receptors are endocytosed and 
can be either recycled to the plasma membrane or trafficked towards degredation. A shift towards 
receptor degredation would result in overall downregulation of receptor density. 
Morphine does not cause endocytosis of the MOR to the same extent that other agonists 
do, and because of this, the opiate receptors are activated for prolonged periods of time and lead 
to cAMP superactivation, a mediator of both tolerance and withdrawal. Recent reports suggest 
that unlike other agonist-induced endocytosis via arrestins, morphine produces desensitization via 
protein kinase C (PKC). In Chinese hamster ovary cells, morphine does not produce MOR 
endocytosis after 2 hrs (as compared to a typical opiate agonist). This lack of endocytosis was 
reversed by pre-treatment with a PKC inhibitor, suggesting that PKC is a mediator of resistance 
to endocytosis caused by morphine15. This mechanism is known as heterologous desensitization 
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because the PKC actually acts on the alpha-subunit of the G-Protein complexed with the MOR 
and not the MOR itself16. 
Dr. Whistler and colleagues17 have proposed the RAVE hypothesis to describe opiate 
tolerance, in an effort to link the concepts of desensitization and endocytosis. The RAVE 
hypothesis involves a ratio which is calculated from “relative activity (RA)” of an agonist to 
activate potassium current and the “versus endocytosis (VE)” component. Each agonist can be 
assigned a ratio (compared to a standard ratio) based on its tolerance inducing mechanisms and 
agonists like morphine which induce very little endocytosis are assigned a high RA/VE number. 
This ratio was hypothesized to predict which type of tolerance would develop based on agonist 
properties. For example, in agonists with high RA/VE, intracellular compensatory mechanisms 
(AC, CREB, etc) would promote tolerance, and with low RA/VE fewer intracellular enzyme and 
protein changes would occur because endocytosis is the primary mechanism of tolerance. Opiates 
with a lesser RA/VE such as methadone and etorphine produce less tolerance when administered 
chronically than dose equi-analgesic doses of morphine.  
In a subsequent study by the same group18, the effects of morphine and methadone were 
tested on the wild-type and two mutated versions of the MOR (see Figure 2). In the D-MOR 
receptor, the entire cytoplasmic tail of the MOR was replaced by the cytoplasmic tail of the delta 
opioid receptor (DOR). This mutant was chosen because it would confer on the mutated cells the 
ability of morphine to cause endocytosis, and like the WT DOR, the endocytosed receptors would 
be targeted for degredation. The R-MOR is a variant of this D-MOR where particular residues of 
the WT MOR tail were left in place, such that the receptor would be endocytosed, but recycled 
back to the plasma membrane as opposed to degraded. Lastly, a MOR with alanine mutations (A-
MOR) in the c-terminal tail was used as “loss of phenotype” construct because even agonists like 
methadone that typically induce endocytosis were unable to. 
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Using these four receptor types in a 
series of elegant experiments, the authors 
showed that activated receptors which were 
more readily endocytosed (low RA/VE 
numbers) were associated with less cAMP 
superactivation and these cells developed less 
in vitro tolerance. When receptors remain 
chronically activated on the surface, there is 
an upregulation of gene expression including 
adenylyl cyclase via CREB. Taking this line 
of experimentation a step further, the authors created a “knock-in” mouse which expressed a 
MOR with the added ability to be readily endocytosed upon morphine binding. Compared to 
controls, mice which expressed this mutant MOR showed enhanced morphine-induced 
antinociception, reduced morphine tolerance and reduced naloxone-precipitated withdrawal19. 
Downregulation 
Receptor downregulation can occur as a result of either decreased transcription / 
production or enhanced degredation. The fate of endocytosed opiate receptors to plasma 
membrane recycling versus degradation in the lysosomal system is likely determined by specific 
protein interactions between the C-terminal end of the GPCR and the G-protein-coupled receptor 
associated sorting protein20. Modulation of the c-terminal end of the MOR can affect tolerance 
mechanisms as described above. 
There have also been studies looking at production of opiate receptors. Cell culture 
models have investigated mechanisms of translational downregulation of the MOR. MicroRNAs 
(miRNA) bind to post-transcriptional MOR mRNA and sequester it to P-bodies, leading to a 
decline in translation in a miRNA concentration dependent manner. Inhibitors of this miRNA 
 
Figure 2:  A RAVE about Opioid Withdrawal 
Alvarez et al; Neuron; December 2001 
*copyright request granted 
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(allowing an increase in MOR translation) led to attenuation of opioid tolerance in a mouse 
model. Experiments in morphine exposed rats show brain-area specific downregulation of MOR 
transcription (mRNA levels) after 7 days of continuous therapy. Specifically, the hypothalamus 
shows decreased transcription, but not the locus ceruleus, the ventral tegmental area, or the 
nucleus accumbens21. Brain specific regulation of MOR is not currently well understood but is an 
active area of investigation. In mice, etorphine (but not morphine) therapy for 7 days led to a 30% 
decrease in spinal cord MOR density. Of note, treatment with either drugs produced tolerance 
with a shift in ED50 by approximately 7-fold22. So although morphine is known to cause 
tolerance, there absolute role of receptor downregulation is still an active area of study. 
Novel Understanding of the Role of N-methyl-D-aspartate receptor (NMDA) Receptors 
Recent increased molecular understanding of the intracellular events leading to tolerance  
suggest that most pharmacologic approaches used to attenuate morphine tolerance act somewhere 
on the pathway that links the activity or MOR and NMDA receptors (NMDARs). In mice, 
NMDA receptor antagonists prevent morphine tolerance and decrease the development of 
physical dependence as manifested by a naloxone precipitated withdrawal after chronic exposure 
to morphine23. Clinical evidence supports this hypothesis in clinical trials which co-treat post-
operative pain with morphine and ketamine (an NMDA antagonist). Ketamine treated patients 
show decreased pain scores, decreased cumulative morphine consumption and decreased post-
operative desaturations events compared to opiate monotherapy patients24. There are multiple 
case reports of ketamine used to rescue severely opiate tolerant patients with severe pain25-27. 
Proteins involved in the cross-regulation between MOR and NMDARs include PKC, 
neuronal nitric oxide synthase (nNOS), G-alpha subunits and regulators of G-protein signaling 
(RGS) proteins. Sub-families of these proteins are expressed almost exclusively in neuronal tissue 
and are known to affect the MOR activity. At the intracellular c-terminal end of the MOR, 
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regulator proteins mediate the interaction between the NMDAR and MOR28 and also allow for 
binding of RGS proteins, recruiting neuronal nNOS and regulating NO production. Under the 
influence of zinc availability, regulated by NO, tolerance mediators such as PKC discussed above 
are controlled. Details of the molecular mechanisms known to facilitate the cross-talk between 
MOR and NMDARs are beyond the scope of this introduction, but a very thorough review has 
been presented by Dr. Garzon and colleagues in Current Drug Abuse Reviews29. 
Morphine Dependence Mechanisms 
Tolerance can either be acute (with cellular responses observed after one dose of opiate) 
or chronic, with the latter likely reflecting a more profound and entrenched change in cellular 
function and intracellular networking after days to weeks of opioid administration. Physical 
dependence is manifested as withdrawal, with peak signs and symptoms appearing when opioid 
receptor occupancy declines to a minimum, but the symptoms can last for days to weeks in 
humans. Isolated desensitization or the “uncoupling” of the MOR from its downstream effectors 
is likely not the major culprit in dependence and withdrawal as discussed above. These more 
chronic phenomena are more likely the consequence of derangements in intracellular physiology, 
transcriptional and translational changes and adaptations / plasticity in the neuronal networks.  
General Caveats in Translating In Vitro Studies to Living Organisms 
At the end of this introduction, it must be discussed that there is no direct and simple 
relationship between what is observed in cell culture and what is clinically relevant for a human 
manifesting opiate tolerance or withdrawal. For example, it has been shown that the extent of 
uncoupling of MOR from G-protein mediated signaling differs among different neuron types30, so 
within different areas of the central nervous system, different mechanisms are contributing to 
opiate effects. Secondly, most in vitro experiments focus on one pathway of tolerance (i.e. G-











Neonates are commonly exposed to opiates and benzodiazepines for analgesic and 
sedative effects in the intensive care unit (ICU). Although their use is warranted, there are few 
evidence-based resources to guide initiation, maintenance and weaning of analgesic and sedative 
medications. Secular trends in opinions about need to treat pain in neonates have shifted over 
time, from thoughts that infants could not feel pain to a realization that neonatal pain perception 
is intact31. Recently, the growing clinical perception is that the use of opiates in the Neonatal and 
Pediatric Intensive Care Unit is rapidly increasing and this increasing opiate exposure in the 
neonatal period is not without consequence 32. 
There is a fine balance between treating pain and avoiding the adverse events associated 
with opiate exposure, both clinical and cellular. Animal evidence suggests that pain control with 
morphine attenuates long-term negative consequences such as hyperalgesia 33. A recent 
systematic review34 compiled multiple studies which associate painful procedures in the neonatal 
period to adverse neurologic outcomes; so there is indeed a need to minimize the experience of 
pain during a window of critical central and peripheral nervous system development.Conversely, 
animal data suggests that opiates given in the absence of pain may cause adverse cellular changes. 
In the rat, repeated morphine administration leads to long-term alterations in neurochemicals in 
the hippocampus 35. Morphine administration for six consecutive days in neonatal rats leads to 
increased supraspinal neuronal apoptosis in distinct anatomic brain regions, namely the cortex 
and the amygdala 36. The negative effects of long-term opiate treatment in the developing human 
brain are not currently understood outside of clinical manifestations of tolerance and physiologic 
dependence.Although it is understood that pain cannot go untreated in the Neonatal ICU, the 
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growing concern that long-term and high dose opiate therapy is likely not benign prompted our 
group to look more closely at trends in opiate exposure in a tertiary referral NICU over one 
decade. The aim of this study was to investigate changes in the use of analgesic-sedative therapy 
and the rates of iatrogenic NAS over time in critically ill infants over three time epochs: fiscal 






This study was a retrospective cross sectional cohort study which included medical 
record extractions from fiscal years 2003-2004, 2007-2008 and 2010-2011 of all inborn infants 
admitted to Johns Hopkins Hospital with high risk diagnoses. After IRB review and approval, the 
billing office queried discharge diagnosis ICD-9 codes including 746.7 and 745.11 representing 
Hypoplastic Left Heart Syndrome (HLH) and Double Outlet Right Ventricle (DORV), 756.6 
representing congenital diaphragmatic hernia (CDH), 747.83 representing persistent fetal 
circulation (PPHN), 756.73 and 756.72 representing gastroschisis and omphalocele (G/O), 765.21 
and 765.22 representing 24 completed weeks of gestation and less than 24 completed weeks of 
gestation (<25 weeks). These diagnoses were chosen because they include infants who are likely 
to require longer duration of mechanical ventilation, have had major surgeries and multiple 
painful procedures and thus are likely to have received opiate treatment. The infants identified by 
diagnostic billing codes then underwent discharge summary review (in the electronic medical 
record (EMR)) to decide if they met inclusion criteria. 
Inclusion criteria included all inborn infants at Johns Hopkins Hospital, carrying one of 
the afore-mentioned ICD-9 codes and living for a minimum of seven days. Infants who died 
before seven days of life were excluded because they represent an extreme form of clinical 
severity that is not representative of the typical ICU infant. In addition, infants who were 
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transferred to an outside hospital in less than seven days were excluded because the primary 
outcome of the study, chronic cumulative opiate exposure, could not be measured in these infants. 
Outborn infants were excluded because any opiate exposure at an outside institution or in 
transport would have been difficult to accurately quantify. In order to make the groups across 
time comparable, we also used disease-specific exclusion criteria. For HLH and DORV, the 
infant had to undergo open-heart surgery during their initial inpatient stay (including pulmonary 
artery banding). Infants discharged with no procedures or cardiac catheterizations alone were 
excluded. For PPHN, infants had to be full-term at birth, have cardiorespiratory failure requiring 
intubation but not necessarily nitric oxide therapy. Infants with only nasal canula, BiPAP or 
oxyhood therapy were excluded. Also, infants with PPHN associated with structural cardiac 
defect, genetic syndrome or pulmonary hypoplasia were excluded. The infants with severe 
secondary PPHN are not representative of the majority of this cohort who had transient PPHN 
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6 Lived < 7 days 
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Every eligible patient chart was thoroughly reviewed and demographic data, length of 
stay and need for transfer to step-down facility, pertinent secondary medical diagnoses, surgical 
procedures and need for Extra Corporeal Membrane Oxygenation (ECMO) were extracted. In 
addition, every dose of opiate written as either a one-time, standing intermittent, continuous 
infusion or continuous background infusion as part of Parent / Nurse-Controlled Analgesia 
(PNCA) orders was extracted and converted to morphine equivalents. Opiates extracted include 
morphine, fentanyl, hydromorphone, methadone and diluted tincture of opium (DTO). The 
conversion metrics used to convert non-morphine opiates to morphine equivalents are listed in 
Table 1. The medication orders were in electronic form for the 2010 cohort, but in paper form for 
two prior cohorts. One time or standing PRN orders or “as needed” opiate doses were excluded 
because the documentation was not always available in the paper charts. 
In addition to opiate orders, orders for other types of medications were extracted. These 
included one-time or standing orders for paralytics (vecuronium and pancuronium) and one-time 
or standing orders for benzodiazepines (midazolam, diazepam, lorazepam). In an effort to identify 
a group of medications that would indicate overall degree of intensity of medical intervention, it 
was decided that antimicrobials, and specifically days on antimicrobials, would be a marker of 
changes in medical intervention intensity over time. We chose antimicrobials as a “control” for 
medicalization because their use is potentially more resistant to secular trends than other markers 
of medical intervention such as days of ventilation or days of intravenous nutrition. Orders for 
ampicillin, gentamicin, cefotaxime, vancomycin, cefepime, clindamycin, piperacillin, 
amoxicillin, metronidazole, acyclovir, fluconazole, and amphotericin were extracted. For 
paralytics, benzodiazepines and antibiotics, total days treated with these medications were 
calculated for each patient.  
For the purposes of data analysis, NAS was defined in two ways: 1) the presence of a 
billing code or discharge diagnosis of iatrogenically acquired NAS in the patient record, or 2) the 
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need for weaning of opiate medications over > 1 day. NAS is measured with the Modified 
Finnegan Score in the NICU, and individual NAS scores were not extracted. 
 
Table 1: Opiate Conversions to Morphine Equivalents Although there are multiple published 
opiate conversion algorithms, for the purpose of this study, we chose the conversions used 
clinically in our NICU. We used the same conversions in all three time epochs to make drug 
exposure comparable. It is possible that with other conversion metrics the absolute numbers 
would be different, but the trend would be similar. 
Drug Morphine : Opiate 
Equivalence Ratio 








Fentanyl* 20:1 Always IV 
Hydromorphone 5:1 Always IV 
Methadone 10:1 1:1 
Diluted Tincture of Opium (DTO)¥ 0.4:1 Always Oral 
*Fentanyl conversions derived from Simons et al37 and Saarmenaa et al38 




The primary outcome is cumulative mg of morphine equivalent per infant. The per-infant 
result is then transitioned to a population measure such as mean or median per time epoch. The 
secondary outcomes are the need for opiate weaning (a surrogate marker for NAS) and a 
discharge diagnosis of NAS. STATA version 10.0 was used for all statistical analyses. 
Exploratory data analysis was performed and then continuous variables were compared between 
groups with Kruskal Wallis ANOVA. Categorical variables were compared using chi squared 
test. Univariate regression was then used to test if time epoch was a statistically significant 
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predictor of cumulative Mg of morphine equivalents in both a linear (primary) and quintile 
(secondary) analysis. A p-value of less than 0.05 was considered statistically significant.  
 
Results 
Billing inquiry revealed 82, 68, and 88 unique patients for FYs 2003, 2007 and 2010 
respectively. Please see Figure 1 for a flow diagram of inclusion and exclusion criteria. After 
multiple rounds of chart review, the final cohort for each year was finalized and the demographic 
information is presented in Table 1.2. The length of inpatient stay, the percentage of patients who 
underwent major surgery and who were placed on ECMO did not differ statistically between 
groups. Days treated with any antibiotics, a marker of overall medicalization, did not differ 
between groups (Figure 5). Although it did not reach statistical significance, there were more 
infants transferred to outside facilities while still treated with opiate medications in the later time 
period. 
 
Table 2: Infant Demographics  
 FY 2003-2004 FY 2007-2008 FY 2010-2011 P-Value 
Total Number Infants 21 14 28  
Primary Diagnosis, N (%)    0.429  
  GA < 25 weeks 7 (33) 7 (50) 6 (21)  
  PPHN 6 (29) 2 (14) 6 (21)  
  HLH / DORV 5 (24) 4 (29) 6 (21)  
  Gastroschisis/Omphalocele 1 (5) 0 4 (14)  
  CDH 2 (9) 1 (7) 6 (21)  
     







     
Inpatient Stay, days 
   Mean (SD) 












Thoracic / Abdominal Surgery, N 
(%) 
14 (67) 9 (65) 24 (86) 0.191  
ECMO, N (%) 4 (19) 1 (7) 4 (14) 0.615  
     
Days on Antibiotics  
   Mean (SD) 














     
Transferred on Opiates, N (%) 1 (5) 2 (14) 6 (21) 0.256  
Died prior to hospital Discharge, N  3  1 1 0.387  
*Inpatient stay does not include days spent at step-down facilities 
 
 
 The primary analysis of average cumulative opiate exposure modeled as a continuous 
variable in a linear regression did not reach statistical significance. On average, there was a 134 
mg increase in opiate exposure for each subsequent time period (95% CI -12, 279, p-value 0.071).  
Because the data was not normally distributed with a strong right skew, we undertook a 
secondary analysis comparing the median exposures. This secondary analysis involved regression 
modeling of the median exposure per time epoch. The median cumulative opiate exposure per 
infant increased from 10 mg to 25 mg to 114 mg, and this was statistically significant with an 
average increase of 45 mg (95% CI 2.6, 88, p-value 0.038). Trends in cumulative opiate exposure 
are displayed in Figure 4. 
 
The percentage of infants who carried a discharge diagnosis of iatrogenic NAS 
significantly increased over the three time periods from 9% to 36% to 50%, commensurate with 
the increased opiate exposure. There were no statistically significant increases in days of paralytic 
or benzodiazepine exposure over the three time epochs (Table 3), suggesting that opiate exposure 
was the main difference in sedato-analgesic use. 
 
Table 3: Iatrogenic Medication Exposure and Neonatal Abstinence Syndrome 







Cumulative Morphine  
Equivalents per Infant,  
Mg 
   Mean (SD) 
        linear regression 
   Median (Range) 





134 (-12, 279) 
 






































   Mean (SD) 








      
Days Paralytics 
   Mean (SD) 













   Mean(SD) 












      
Ever Required Weaning of 
Opiate, N (%)* 
 11 (53) 10 (71) 23 (82) 0.068  
Discharge Diagnosis of 
NAS, N (%) 
 2 (9) 5 (36) 14 (50) 0.012  
≠Statistically significant p-values are displayed in bold. 
*There were three children who died before opiate weaning in the 2003-2004 cohort 
 
 
There were two infants identified as outliers, both by statistical (undue leverage and 
Cooks D test) and clinical measures. These two infants both had cumulative exposures of over 
5000 mg which is greater than 50 times the median in the highest exposure group. The first infant 
born in 2003 was a full-term infant with CDH and severe PPHN who required greater than two 
weeks of ECMO support, was treated for MRSA meningitis and received a Nissen/GT prior to 
discharge to step-down facility after an 102 day admission. The second infant born in 2010 was 
also a full-term with CDH, severe PPHN who was treated with ECMO for > 2 weeks, and was 
transferred to step-down facility after a 102 day admission with continuing treatment with 
methadone, valium and clonidine. As a comparison, all other infants on ECMO in the cohorts 




























This is the first study of which we are aware that attempts to quantify exact amounts of 
opiate exposure in the neonatal ICU population and to compare this exposure over time. The most 
important finding of this study is that medical opiate exposure is increasing over time in very high 
risk neonates in the ICU setting. Although Neonatal Infant Pain Scores (NIPS) were recorded 
during opiate therapy, they are not solely used to titrate medications because other factors 
including agitation, movement during wound healing with multiple invasive lines and tubes, 
endotracheal tube stability and synchronicity with mechanical ventilation, and oxygenation and 
ventilation status are often considered when titrating opiates. It is possible that pain control also 
improved concomitantly over this time period, but this is speculative as data on pain scores were 
not extracted from the charts for the reasons mentioned above. There were no systemic changes in 
pain management or pain protocols implemented during the time period studied. In addition, the 
practitioners in the NICU did not use pain treatment protocols or opiate weaning guidelines over 
the time period under study. 
Although this study is limited to one tertiary care ICU, it is possible that this trend is 
more widespread than currently appreciated. The goal of this study is to provide a first glimpse 
into the cumulative amount of opiate received by an infant during an ICU stay. Because our study 
is limited in sample size and the data are not normally distributed, we were unable to perform 
meaningful regression analyses adjusting for all factors which might contribute to increasing 
opiate therapy, so definitive conclusions cannot be made until this study is replicated in a larger 
cohort. The sharp increase in cumulative opiate exposure is supportive of the impression among 
physicians that we are seeing an increase in the number and severity of iatrogenic Neonatal 
Abstinence Syndrome. These infants with prolonged, high dose opiate exposures become 
physiologically dependent and have withdrawal once weaning is initiated, leading to prolonged 
inpatient and, at times, outpatient weaning programs. 
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One prior study has investigated medical opiate exposure in neonates weighing less than 
1500 grams who were ventilated from day of life one across six different NICUs 39. Unlike our 
study which aims to quantify cumulative exposure, this prior study addressed exposure as binary 
on three different hospital days. Opiate exposure varied by birth weight, illness severity and site. 
There was a 28-fold variation in opiate administration between the six study sites. 
Sedato-analgesic medications are an important part of ICU care. Studies have shown 
decreased markers of physiologic stress 40, improved hemodynamic stability 41 and improved 
synchrony with the ventilator 42, but these are all short-term outcomes and the long term effects of 
substantial opiate exposure in the immediate neonatal period are unknown. Given the lack of 
long-term studies, medical opiate exposure should be closely examined and efforts to curtail 
further increases may be warranted. The increase in exposure could be due to many clinical 
possibilities. For example, there could be secular trends in using more opiates for sedation, 
aggressiveness of opiate weaning, or tolerance of withdrawal symptoms vs markedly slow and 
prolonged weans in an effort to keep infants symptom free . Although we were unable to explain 
the etiology behind the increase in medical opiate exposure with this retrospective study, we still 
feel this is a trend worth discussing. Both clinical and research paradigms that are geared towards 
a lowest effective dose strategy and incorporate a multi-modal pain control approach might lessen 
the exposure to opiate medications. One barrier to weaning opiate medications is reliance on 
withdrawal scores which have not been well validated in sick, ventilated and post-operative 
infants. In addition, there are few well-validated sedation scores in the neonatal population, the 
use of which may prompt clinicians to recognize over-sedation or over-narcotization and wean 
opiate medications more readily. 
There are potential confounders to our study results. Although not statistically significant, 
there was an increased length of stay, increased use of paralytics to medically manage, and an 
increased rate of thoracic or abdominal surgery over time, all of which could partially account for 
the increase in exposure to opiates. Despite these potentially clinically meaningful trends, the 
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degree of increase in opiate exposure over time cannot be fully explained by these factors. A 
multimodal approach to pain and sedation therapy and to minimizing opiate withdrawal 
symptoms often includes use of a benzodiazepine. We considered that the decreased use of 
adjunct benzodiazepines for pain and sedation might explain the increase in opiate exposure we 
observed, but there was no difference in the days of benzodiazepine exposure over time in our 
data. The measure of benzodiazepine exposure we chose to extract from the charts was “days of 
exposure” as opposed to cumulative doses, and it is possible that if we had assessed 
benzodiazepines in a more granular fashion, the increase in opiate exposure would be explained 
by a decrease in cumulative benzodiazepine exposure.  
There are limitations to our study. In regards to opiate, benzodiazepine and paralytic 
exposure, the charts were extracted for standing doses only – meaning that due to heterogeneity 
and missing data in charting of PRNs over the three time epochs, we chose not to include PRNs 
in our calculations of exposure. A potential interpretation of our results is that in the earlier time 
epochs, more PRN opiate doses may have been used instead of standing orders or infusions. In 
addition, other non-opiate medications used for pain control were not extracted (i.e. NSAIDs, 
Acetaminophen), so it is possible that a reverse trend in non-opiate use could explain the rise in 
medical opiate use. Lastly, the increase in opiate exposure could partially be explained by 
changes in prescribing patterns, i.e. doctors using more methadone in later epochs and using more 
lengthy opiate weaning strategies. Even if these potential scenarios were the case, such a sharp 
increase in exposure to opiates from any form of standing orders and infusions is still worth 
investigating.  
Regarding secondary endpoints, there was no very clear way to retrospectively capture 
every infant who manifested signs of physical opiate dependence, so we chose to measure both 
rates of diagnosis of NAS and also the number of infants who required weaning of their 
medications. These are imperfect measures and we acknowledge that weaning of opiates may be 
a preventative strategy to mitigate signs of NAS. Additionally, because we did not analyze 
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cumulative benzodiazepine exposure, it is possible that the increase in NAS observed in these 
infants was a result of a combined withdrawal from increasing opiates and benzodiazepines. 
There are issues with current methods of quantifying withdrawal from medical opiate exposure in 
newborns. First, many scoring tools used in the NICU43,44 are only validated for withdrawal from 
in utero opiate exposure but are used because the clinical syndromes of withdrawal are thought to 
be sufficiently similar. Second, there are scoring tools validated for medical opiate and 
benzodiazepine withdrawal in pediatrics45, but they are not well studied in infants less than 6 
months of age. 
It is also possible that opiate exposure is increasing over time because the care is “more 
intensive” overall.  In an effort to measure intensity of care, we collected the number of days on 
the most commonly used antibiotics and antifungals. There was no significant change in 
antibiotic exposure in the time frame studied. This could imply that opiate exposure is increasing 
not as a function of overall increased medicalization, but as a unique entity. 
Although the increase in discharge diagnosis of NAS could be due to changes in accuracy 
of billing or increased recognition of this syndrome, given the increase in opiate exposure, it is 
more likely secondary to a true increase in the incidence of physical withdrawal behaviors. The 
fact that the cumulative opiate exposure per infant during the inpatient stay rose despite the fact 
that an increasing number of infants were transferred to outside hospitals still treated with opiates 
is a testament to the overall increasing opiate exposure. 
 
Conclusion 
Although analgesia with opiates is important in the most critically ill neonates, it may be 
time to readdress our current sedative-analgesic practices and move towards more aggressive 
attempts to limit the amount and duration of opiate exposure in the ICU. Studies which address 





Optimization of Morphine Dosing for NAS using Population Pharmacologic Modeling 
An important step in understanding how to rationally dose medications involves 
understanding how the administered dose relates to exposure and response. Pharmacokinetics 
(PK) is the study of drug absorption, distribution, metabolism and elimination – and one of the 
main goals of PK studies is to understand how dose relates to exposure by estimating values such 
as clearance, volume of distribution, etc. Traditional PK approaches used in adult patients involve 
intense blood samples and creation of concentration – time curves for each individual, and then 
averaging these curves to understand the distribution of exposures controlling for dose. This 
traditional approach is often unrealistic in the smallest patients because the frequency of blood 
draws and the volume of blood required for this “rich data” type of analysis is not feasible. 
 
Population pharmacokinetics or “PopPK” is a discipline which arose in the 1970s, and 
offers an alternative methodology for estimated PK parameters with more sparse and uneven 
concentration data. Both traditional PK studies and population PK studies have the same goals, 
but the statistics used are quite different and there is the potential for decreased clinical 
application due to the complexity of the analyses and inability of practicing clinicians to follow 
the logic. 
 
Population analysis, also known as non-linear mixed effect modeling, is a method to 
integrate and model the data collected from more than one individual in an effort to understand 
both the average response, or drug concentration, and the variability in this response. This 
methodology takes into account variables that are known (time, dose) as “fixed effects” and can 
quantify random effects after accounting for patient specific traits. This approach allows for 
robust PK analyses with sparse and uneven sampling designs, giving vulnerable populations such 
as neonatal and pediatric ICU patients the ability to be part of clinical pharmacology research 
using novel sampling methods such as opportunistic sampling with clinical blood draws and 
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scavenged sampling. A very powerful tool of population analysis is that you can understand and 
quantify the variability due to specific patient factors or covariates, with the potential to 
individualize dosing. 
 
Population PK parameters contain multiple layers and include the population mean, the 
interindividual variability, and the residual variability. The models built using the PopPK 
approach can be internally validated by assessing model goodness-of-fit, bootstrapping, visual 
predictive checks, and assessing the normalized prediction distribution error. In addition, models 
must ideally be externally validated by applying a different set of data (not used for model 
building) and testing model performance. Ultimately and most importantly, the model can be 
used to simulate exposures and the variability in exposures when different doses are given to 
future patients. George Box, one of the great statistical minds of the 20th century, once wrote 
“Essentially all models are wrong, but some are useful.” With this humbling reality in mind, the 
aim of the second portion of this thesis research was to prospectively develop a population PK 
model of enteral morphine and its glucuronide metabolites in neonates with moderate to severe 
Neonatal Abstinence Syndrome. 
 
As displayed in the figure below, this model building step is the input for a future 
iterative process in which you can define clinically relevant endpoints and goals and use these 
goals to pose questions to the model. With a clinical goal and range of potential doses in mind, 
you can simulate the variability in responses within a population and then refine your questions 
and model until you feel confident moving forward with a clinical trial with new dosing 
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Population Pharmacokinetics of Enteral Morphine and its Glucuronide Metabolites 
in Neonatal Abstinence Syndrome 
 
Introduction:  
Morphine has been used for neonatal pain control and sedation for decades. In part due to 
a lack of a well defined pharmacokinetic-pharmacodynamic link, the prescribing practices 
between intensive care units is extremely variable46. In addition to pain control and sedation, 
morphine is one of two first line opiates for the treatment of neonatal opiate withdrawal 
syndrome, known as Neonatal Abstinence Syndrome (NAS). Infants who were exposed to opiates 
either in utero or as part of medical care are at risk for the development of NAS. In a national 
survey of management of in- acquired NAS47, morphine sulfate was by far the most commonly 
used first line agent for both opiate and polysubstance withdrawal. Despite common first-line use, 
this study also found that there were 23 different treatment regimens reported from 211 neonatal 
units, with doses ranging from 10-400 mcg/kg administered 2-8 hourly. The 2010 Cochrane 
review of opiates for NAS found a significant benefit of treatment with opiate vs 
benzodiazepines, but there is insufficient research to determine the best opiate medication and at 
which dose48. Despite the widespread use of morphine as the first line agent in NAS, the 
pharmacokinetics of the enteral formulation have not been studied.  
The pharmacokinetics of parenterally dosed morphine in infants and children have been 
well described49-51; as shown in an evaluation of currently published population models52,  the 
greatest differences in predicted morphine clearance values between the models are observed in 
the first month of life. This is very pertinent to NAS treatment because by definition infants with 
NAS are treated with enteral morphine within the first month of life. One publication has assessed 
modeling morphine across all age ranges using a bodyweight dependent exponent for maturation 
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of clearance53.Using an allometric exponent which decreased in a sigmoidal manner with 
bodyweight, there was no need to use additional covariates for size or age. This model drew upon 
a diverse range of patient ages and study designs and adds a novel approach for allometric scaling 
of morphine clearance. 
In an effort to further understand the pharmacokinetics of enteral morphine in the first 
weeks of life, we undertook a prospective observational study off fullterm neonates treated with 
enteral morphine for in and ICU acquired NAS. Our aim was to quantify the first pass 
metabolism by building upon prior published models of parental morphine data and to better 
understand the proportion of parent drug metabolized to varying glucuronide metabolites. In 
addition, we sought to confirm the prior identified patient covariates that influence morphine 
disposition in early infancy. By collecting the standardized pharmacodynamic marker of 
withdrawal scores in a controlled population, we hope in future studies to establish a PK-PD link 




Patient Population  
The study was approved by the Johns Hopkins Medical Institution IRB. Between the 
years 2012-2014, all mothers who delivered infants at risk for NAS due to in utero methadone or 
heroin exposure were approached for consent at a large multi-site academic hospital system. Once 
parental consent was obtained, infants were monitored closely for NAS using the Modified 
Finnegan Withdrawal Tool (Finnegan reference) and were only enrolled in the study if they 
required opiate therapy due to threshold severity of withdrawal symptoms. Once started on 
enteral morphine therapy, the daily times and doses of administration and the every three to four 
hourly NAS withdrawal scores were collected and entered into an electronic database. Plasma 
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samples were collected via heelstick puncture for capillary samples up to four times over the 
entire study period for quantification of drug and metabolite concentrations. In addition to in 
uteroacquired opiate withdrawal, infants with ICU acquired NAS who were treated with enteral 
morphine were also eligible for study entry and parents were consented when infant was 
transitioned from IV opiates to enteral morphine during clinical care. 
 
Sample Processing and Quantitative Analysis 
Heelstick whole blood samples were refrigerated for less than 24 hours and then were 
centrifuged to isolate the plasma. Plasma samples were frozen at -80C until batch analysis via 
HPLC (High-performance liquid chromatography )-MS/MS techniques. 
Certified reference standards of morphine, morphine-3-β-glucuronide, and morphine-6-β-
glucuronide, as well as a single lot of the isotopically labeled internal standards (IS) morphine-d3 
morphine-3-β-glucuronide-d3, and morphine-6-β-glucuronide-d3, were all purchased from 
Cerilliant Corporation (Round Rock, TX). Drug-free serum was obtained from BioRad 
Laboratories (Irvine, CA). HPLC grade water and methanol were purchased from Fischer 
Scientific (Pittsburgh, PA) and formic acid was acquired from Sigma Aldrich (St. Louis, MO). 
For selectivity, matrix effects and endogenous studies, remnant human serum was acquired from 
vacutainer serum separator tubes (SST) (BD, Franklin Lakes, NJ) and plasma for the plasma to 
serum comparison from lithium heparin tubes (BD, Franklin Lakes, NJ) via an Institutional 
Review Board (IRB)-approved protocol through The Johns Hopkins University School of 
Medicine. All certified reference standards previously mentioned were diluted in methanol 
(MeOH) to prepare separate working calibrator and quality control stock solutions using two 
different lot numbers of each compound to increase assay robustness. A methanol protein 
precipitation solution containing 50 ng/mL of each internal standard was prepared and stored at -
20 °C until used. 
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During sample preparation, protein precipitation was accomplished by adding 500 µL of 
the methanol containing internal standard to 50 µL of each standard, control or sample. The 
resulting solution was vortexed for 30 seconds and centrifuged at 12,000 x g for 5 minutes. The 
supernatant was transferred to a 96-well plate, evaporated to dryness using a 60 °C air stream and 
reconstituted in 500 µL water containing 0.1% formic acid (mobile phase A). An aliquot of 15 µL 
was injected for high-performance liquid chromatographic-tandem mass spectrometric analysis. 
 
A Thermo Scientific (San Jose, CA) Prelude system comprised of an Aria TLX1 system 
equipped with 1250 Transcend pumps and a CTC PAL was used for HPLC. Compounds were 
chromatographically separated using an AccuCore PFP (50 x 2.1 mm, 2.6 µm particle size) 
column that was maintained at 27 °C. Mobile phases consisted of water containing 0.1% formic 
acid (v/v) (mobile phase A) and methanol containing 0.1% formic acid (v/v) (mobile phase B). 
The total analytical run time for this assay was 4.2 minutes. Monitoring of the analytes and their 
respective internal standards was achieved using a TSQ Vantage tandem mass spectrometer 
(Thermo Scientific, San Jose, CA) equipped with a heated electrospray ionization source (HESI). 
Mass spectrometric conditions were optimized by direct infusion of each of the five analytes at a 
flow rate of 10 µL/min and a mobile phase conditions of 50%:50% A:B into the mass 
spectrometer. The instrument was operated in selected reaction monitoring (SRM) and positive 
ionization mode. Product ions were selected based on both ion abundance and consistency in 
fragment ion formation over multiple infusions. The most highly abundant and consistent 
fragment ion was used for drug measurement. These ions matched other previously published 
articles [6, 8]. Quantification of drug concentrations was based on the specific analyte/IS peak 






Population pharmacokinetic model analysis was performed using Phoenix NLME 1.3 
(Pharsight, Cary, North Carolina). The first order conditional estimation method with interaction 
(FOCE-I) was used in the modeling process. Using this estimation method, the interaction 
between BSV (between subject variability and WSV (within subject variability) is taken into 
account. All the plots were generated using Phoenix or R 3.0.2(R Foundation for Statistical 
Computing, Vienna, Austria). 
Model building was performed in four steps: (1) selection of structural model, (2) 
selection of statistical sub-model, (3) covariate analysis, and (4) model validation. The goodness-
of-fit plots for the analysis including observed vs. individual predicted concentrations and vs 
population predicted concentrations were evaluated.  
Because the number of data points used in model building was limited, we chose to 
analyze the morphine and glucuronide concentrations using multiple prior published structural 
models and pharmacokinetic profiles drawing on literature from infants, children and adults. We 
fixed the PK parameters of clearance and volume to known values based on prior information 
(see Table 6) and used the current neonatal data to estimate the fraction of an enteral morphine 
dose which is absorbed (a modified bioavailability). 
(1) Structural model 
A structural model after intravenous administration was built based on physiological 
consideration and previously published IV morphine pharmacokinetics models in adults. First, the 
compartmental PK disposition studies of morphine and its glucuronide metabolites based on rich 
sampling after intravenous administration in healthy adults were used as the base model54,55. 
These two prior publications provided three separate PK models for parent drug morphine, M3G 





lumbar puncture in setting of leukemia treatment57 and (2) post-op pain58. We found that the PK 
model for IV morphine administration based on allometric scaling alone did not perform well in 
these pediatric populations, and we postulated that this was due to inadequate controlling for 
renal clearance maturation. Using morphine pediatric PK data from various routes of 
administration58 and a function for maturation of extracellular water based on prior data59, the 
final pediatric IV morphine administration model including precise formation fraction estimates 
for M3G and M6G was chosen. 
Once the base structural model was chosen, we added a new gut compartment, and the 
corresponding absorption rate constants for parent drug (Ka), M3G (KM3G), and M6G (KM6G). 
Using the neonatal parent drug and metabolite data, these three absorption rate constants were 
estimated and added to the IV model.  Using the final model, Fa (the total amount of morphine 
absorbed into the systemic circulation) was estimated. 
Fmorphine = Ka / (Ka+K3+K6)*Fa 
FM3G = K3 / (Ka+K3+K6)*Fa 
FM6G = K6 / (Ka+K3+K6)*Fa 
(2) Statistical Model 
Between-Subject Variability (Interindividual Variability)  
Between Subject Variability (BSV) for clearance and volume of distribution was 
modeled assuming a log-normal distribution: 
                  (1) 
      
where P is the post hoc PK parameter (such as Clearance), tvP is the typical value of that PK 
parameter (such as tvC), and   i s the corresponding between subject variability. Between subject 
38 
 
variability of clearance and volume of distribution were re-estimated from the data in this study 
using the prior described structural model as a base.  
Within-Subject Variability (Residual Error) 
Within Subject Variability (WSV) was modeled using a proportional error model: This 
proportional error model assumes that the residual error in the model is proportionally dependent 
on the corresponding drug concentration. For example, the higher the concentration, the higher 
the residual error.  
 
DV = C     ε)         (2) 
 
In this model, DV is the dependent variable, in this case concentration. 
 
Bioavailability 
For interindividual variability in bioavailability, an additive between subject variability in 
the logit scale model was used as follows: 
                
     
        (3) 
     
Where  
     
 is the between subject variability for THETA. For consistency and interpretation 
purpose, the additive between subject variability for THETA was transformed to between subject 
variability for bioavailability (F) in a multiplicative scale using the formula as follows: 
 
 
                     
 
       (4) 
    
This equation includes the typical value for F (     and OMEGA-squared THETA which is the 
variance of between subject variability (BSV) on THETA. 
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(3) Covariate Model 
Based on prior publications of morphine PK in infants, age was considered as a 
potentially significant covariate. The age effect on maturation of central volume of distribution 
and clearances were included in the final models. The maturation of morphine clearance was 
borrowed from a previous a publication directly60. However, the maturation of morphine 
distribution was newly modeled based on physiological considerations. Morphine is mainly 
distributed in extracellular water, which is represented by the central volume of distribution in the 
base three compartment model. The physiological maturation of extracellular water as a 
percentage of body weight was published in previous work59 and was used to further adjust the 
maturation of morphine distribution after considering the allometric scaling approach. A digitized 
extracellular water maturation curve was fitted by an exponential model as shown in Figure 7. 




Figure 7: Maturation of extracellular body water as a percentage of body weight. The red solid 
dots represent digitized data from previous work59. The solid blue line represents model fit. 
 
(4) Model Validation 
Goodness-of Fit Plots 
Model selection was driven by the data and was based on various goodness-of-fit 
indicators, including comparisons based on the minimum objective function value (OFV), visual 
inspection of diagnostic scatter plots, and evaluation of estimates of population fixed and random 
effect parameters.  
Normalized Prediction Distribution Error 
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Normalized Prediction Distribution Error (NPDE) analysis was performed in Phoenix and 
NPDE R package10 (version 2) in R 3.0.2. Two hundred replications of simulation were 
generated for each observation in the original dataset using the final model in Phoenix. A 
statistical test for normality was automatically generated by the R package. NPDE versus 
population predicted concentrations (PRED) and NPDE versus Time after Dose (TAD) were used 
to determine whether worrisome trends were present suggesting errors in bias or precision. 
Bootstrap 
Nonparametric bootstrap method using Phoenix NLME 1.3 was used to evaluate the 
precision of parameter estimation in the final model. Two hundred replications were generated by 
re-sampling from the observed morphine concentration dataset and PK parameters were estimated 
for each of the replication datasets separately. The median and corresponding 95% percentile 
interval (2.5th and 97.5th percentiles) obtained from the 200 sets of parameter estimations were 
compared to the estimations obtained from First Order Condition Estimation with Interaction 
(FOCE-I). 
Results 
For the analysis, data from 18 prospectively enrolled fullterm infants, supplying a total of 
51 drug concentrations, were used. The 18 infants included three with ICU acquired NAS and 15 
with in utero acquired NAS. Gestational ages at birth were between 35 4/7 weeks to 41 0/7 weeks 
and birth weights were between 1920 grams and 3710 grams (see Table 4). These 18 infants 
provided 51 different samples on which parent drug morphine, morphine-3-glucuronide and 







Table 4: Patient Characteristics in Prospective Cohort (n=18) 
Gestational Age, weeks (median, range) 37 2/7 (35 4/7 to  41 0/7) 
Birthweight, grams (median, range) 2778 (1920-3710) 
  
ICU acquired NAS (%) 3/18 = 17% 
In uteroMethadone-only exposed (%) 11/18 = 61% 
In utero poly-substance exposed 4/18 = 22% 
Non-white race (%)  3/18 = 17% 
 
Among the 18 prospectively collected patients, there were 11 samples in which parent 
drug morphine was < 5 ng/ml and there was a significant amount of M3G detected (median 25.4 
ng/ml, range 9.8 to 316 ng/ml). In all 51 samples, there was more M3G detected than M6G.  The 
ratio of M3G:M6G ranged from 3.0 to 5:1 in 44/51 samples. In the remaining seven samples, the 
ratio ranged from 5.8:1 to 28.5:1 (see Table 5). 
 


















1A 0.1 mg q3 2:46 11.56 76.64 19.6 3.91 
1B 0.1 mg q3 3:00 5.85 45.22 12.28 3.68 
1C 0.1 mg q3 3:00 <5 13.45 <5 13.45 
2A 0.14 mg q3  2:43 8.43 78.41 24.67 3.18 
2B 0.18 mg q3 2:19 13.14 103.21 33.03 3.12 
2C 0.2 mg q3 3:05 11.25 116.39 37.33 3.12 
2D 0.18 mg q3 3:00 5.8 79.62 22.75 3.50 
3A 0.08 mg q3 2:25 32 67.63 21.17 3.19 
3B 0.05 mg q3 0:23 <5 26.2 6.73 3.89 
3C 0.02 mg q3 4:00 <5 24.52 6.56 3.74 
4A 0.08 mg q3 1:02 9.46 48.06 16.14 2.98 
4B 0.08 mg q3 3:15 6.85 43.09 14.07 3.06 
4C 0.08 mg q3 3:04 <5 13.89 <5 13.89 
4D 0.04 mg q3 2:00 <5 19.26 5.73 3.36 
5 0.14 mg q3 1:05 13.74 64.48 16.45 3.92 
6A 0.18 mg q3 0:00 11.2 178.66 47.02 3.80 
6B 0.16 mg q3 1:13 11.88 145.5 39.9 3.65 
6C 0.08 mg q3 0:30 5.49 64.28 17.53 3.67 
6D 0.04 mg q3 1:02 <5 33.12 9.11 3.64 
7A 0.16 mg q3 3:00 5.77 126.07 25.51 4.94 
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7B 0.08 mg q3 1:33 6.02 73.56 14.71 5.00 
7C 0.04 mg q3 3:00 <5 18.42 <5 18.42 
7D 0.02 mg q3 2:18 <5 41.99 8.29 5.07 
8A 0.18 mg q3 2:00 28.15 121.84 30.15 4.04 
8B 0.14 mg q3  0:35 12.4 78.38 19.64 3.99 
8C 0.1 mg q3  1:10 6.84 68.94 14.91 4.62 
9A 0.08 mg q3 0:00 21.43 45.48 10.38 4.38 
9B 0.02 mg q3 3:25 7.55 24.94 7.44 3.35 
10A 0.28 mg q3 3:00 11.21 116.86 32.4 3.61 
10B 0.28 mg q3 2:55 12.39 126.92 33.5 3.79 
11A 0.12 mg q3 3:25 19.48 44.92 9.17 4.90 
11B 0.08 mg q3 3:00 <5 44.92 9.76 4.60 
11C 0.1 mg q3  2:25 7.86 102.56 26.2 3.91 
11D 0.1 mg q3   3:25 10.22 66.31 19.55 3.39 
12A 0.06 mg q3  2:54 9.59 70.96 21.77 3.26 
12B 0.04 mg q3 0:49 7.65 58.47 17.95 3.26 
13A 0.12 mg q3 0:05 8.32 100.67 27.55 3.65 
13B 0.16 mg q3 0:07 9.56 131.81 34.86 3.78 
13C 0.16 mg q3 2:59 8.82 116.07 31.71 3.66 
13D 0.14 mg q3  2:30 8.38 87.57 24.3 3.60 
14A 0.12 mg q3 0:57 20.99 85.68 22.67 3.78 
14B 0.12 mg q3 1:25 31.61 89.5 23.08 3.88 
15A 0.21 mg q6 0:10 <5 28.49 <5 28.49 
16A 0.04 mg q3 0:10 10.54 35.84 10.32 3.47 
17A 0.08 mg q3 0:02 7.36 33.25 10.01 3.32 
17B 0.06 mg q3  0:05 5.59 28.57 8.94 3.20 
17C 0.06 mg q3  3:06 <5 23.97 6.48 3.70 
17D 0.04 mg q3 0:00 <5 9.75 <5 9.75 
18A 0.37 mg q3 3:21 22.03 316.75 66.01 4.80 
18B 0.32 mg q3 0:03 25.84 258.2 54.52 4.74 
18C 0.2 mg q3 0:00 9.05 144.13 24.79 5.81 
 
 
Final Parent Drug Model 
The final covariate models for clearance (CL), the central compartment for volume of 
distribution (V), inter-compartmental clearance (Q2, Q3) and peripheral compartments for 
volume of distribution (V2, V3) are shown as follows: 
tvCL          
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where tvCL is the typical value of clearance and tvV is the typical value of volume of 
distribution. These typical values for total clearance (CL) and central volume of distribution (V) 
were estimated from the above equations using the covariates postmenstrual age (PMA), 
postnatal age (PNA) and body weight (WT) in kilograms. The rest of the parameters in the above 
equation were fixed to the values obtained from the previous publication54. Between and within 
subject variability were newly estimated during the modeling process for morphine clearance, 
volume of distribution and absorption fraction. 
Model for Absorption 
An absorption compartment and first order absorption rate constants were added to the 
prior discussed IV model. The final structure of the pharmacokinetic model is as follows: 
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where Aa is the amount of morphine in the absorption compartment, A1 is the amount in the 
central compartment, A2and A3 are the amounts in the peripheral compartments, and Q2 and Q3 
are the intercompartmental clearance. Bioavailability was modeled logistically to theoretically 
constrain the value from zero to one using equation (15). 
 
  
      
        
          (15) 
           
Final Metabolite Model           
The same approach which was used to build the parent drug morphine population 
pharmacokinetic model was extended to describe the population pharmacokinetics of morphine-
3-glucuronice (M3G) and morphine-6-glucuronide (M6G), the two major metabolites of 
morphine. The formation of M3G and M6G as a result of parent drug morphine metabolism was 
added to the prior described morphine population pharmacokinetic model using two formation 
fraction factors (fmM3G and fmM6) that describe the proportion of the parent morphine 
converted to these two metabolites. Further, the first pass effect on morphine metabolism after 
oral administration was described by the addition of two absorption rate constants for M3G and 
M6G (KM3G and KM6G). The maturation of M3G and M6G elimination clearance (CLM3G and 
CLM6G) was borrowed from a previous publication61 which investigated the maturation of 
elimination clearance via GFR from neonates to adults. 
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The final integrated parent-metabolite model can describe the concentration time profile of 
morphine, M3G and M6G with an absorption fraction parameter Fa instead of bioavailability F. 
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Fa is the total percent of the morphine dose that is absorbed as morphine, M3G or M6G from the 
gut. 
Table 6: Parameter Estimates 
Parameter Units Meaning Estimates BSV Bootstrap  
Estimate 
(95% CI) 
Ka Hour-1 Absorption rate constant parent drug 
 
0.471  0.453 
(0.208, 0.850) 
 
Km3G Hour-1 Absorption rate constant M3G 
 
0.0468  0.0601 
(0.0131, 0.104) 
 
Km6G Hour-1 Absorption rate constant M6G 0.0486  0.0511 
(0.022, 0.093) 
 
      
Fa n/a Absorption fraction 
 
58.9% 8.5% 57.1% 
(50.8, 66.2) 
Vstd§ L Central volume of distribution 
 
17.8 95.6%  
CLstd§ L/hour Parent drug clearance 75.3 68.6%  
      
V2std§ L Second compartment 87.3   
V3std§ L Third Compartment 199   
Q2std§ L/hour Intercompartmental clearance 
 
136   
Q3std§ L/hour Intercompartmental clearance 19.5   
      
VM6G1§ L Central volume for M6G 
 
9.5   
VM6G2§ L Peripheral volume for M6G 
 
7.1   
VM3G1* L Central volume for M3G 
 
8.18993   
VM3G2* L Peripheral volume for M3G 
 
11.9214   
QM6G§ L/hour Intercompartmental clearance M6G 
 
5.8   
QM3G* L/hour Intercompartmental clearance M3G 
 
9.62188   
FmM6G++ - Formation fraction (from parent drug)  
of M6G 
 
4.4 %   
FmM3G++ - Formation fraction (from parent drug) 
of M3G 
 
32.9 %   




CLM3G* L/hour Elimination clearance of M3G 7.82924   
      
stdev0 - Morphine 48.8%  40.5% 
(20.5, 58.8) 
 
stdev1 - M3G 23.1%  22.1% 
(15.1, 29.2) 
 
stdev2 - M6G 27.2%  27.2% 
(19.5%, 35.7%) 
      
HillCL± - Maturation exponent 
 
3.6   
GamR¥ - Steepness of clearance maturation 
curve 
 
3.33   
CLmat50± Weeks Age at which pediatrics reaches 50% 
of adult morphine clearance after 
adjusted by body  
Weight 
 
58.3   
CLRmat50¥ Weeks Age at which pediatrics reaches 50% 
of adult renal clearance after adjusted 
by body weight 
 
55.4   
BetaV# n/a Fractional difference from Vstd at 
birth 
 
0.613995   
Tvol# Years maturation half-life of the PNA-
related changes of V 
0.185467   
 
± Fixed from model published by Holford et al60 
¥ Fixed from model published by Rhodin et al61 
* Estimated from digitizing the PK profiles from Penson et al55 
§ Fixed from model published by Lotsch et al54 
++ Estimated from data in Stuart-Harris et al56 and Lundeberg et al58 




The goodness-of-fit plots showed that the population predicted and individual predicted 
morphine, M3G and M6G concentrations based on the final model were in agreement with the 
observed concentrations (Figure 8). Figure 9 depicts the distribution of NPDE vs time after dose 
(TAD) and vs log concentration for morphine and its metabolites. The dotted lines represent the 





(A)  M3G                                           (B) M6G          (C) Morphine 
 
Figure 8: Observed vs predicted concentrations 
Observed vs population-predicted (upper panel) and individual predicted (lower panel) 










(A) M3G                                           (B) M6G          (C) Morphine 
 
Figure 9: Normalized Prediction Distribution Error (NPDE) is plotted vs Time after Dose and 
Population Predicted Concentration for (A) morphine-3-glucuronide, (B) morphine-6-




This is the first study to characterize the pharmacokinetics of enteral morphine and its 
glucuronide metabolaites in young neonates with ICU and in utero acquired opiate withdrawal. 
We used sparse data to build upon prior published models from multiple populations in order to 
estimate the fraction of enterally dosed morphine absorbed in neonates. We hope to use this data 
as the first step in optimized dosing in this population. It was found that 59 % of a morphine dose 
reaches the systemic circulation in these neonates, an estimate of bioavailability much higher than 
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the 24% reported after oral morphine administration in adults62,63. Although this PK study was 
performed in infants with NAS, this relatively high bioavailability can potentially be generalized 
to other neonates being treated with enteral morphine for post-operative pain or procedural pain. 
Similar to prior published parenterally dosed morphine models, our data confirm the 
importance of maturation (age) and size (weight) on clearance of morphine. Strengths of this 
study include maximized use of prior published morphine PK models in different populations as 
prior data in parameter estimation and model building. Because the pediatric literature is so rich 
for IV morphine PK, it would have been unethical to perform a more traditional bioavailability 
study in these infants, meaning concurrent IV and enteral dosing. Additionally, we were able to 
measure morphine metabolites on very small samples and incorporate these into a universal 
structural model for morphine disposition. 
Potential weaknesses to the study include error introduced in model building and PK 
parameter estimates due to inaccuracy of nursing record of morphine dosing times. All infants in 
the study were known to require exact documentation of doses by nursing staff, so we hope that 
medication and sample time recording error was minimized. Additionally, there is potential for 
model mis-specification given the strong emphasis on prior information, especially when the 
populations used do not exactly match that of the current study. The theory behind this approach 
is that the pharmacokinetics are universal for a given drug, “one drug one model”. The adult 
parameters, once externally validated and proven robust, can be used as prior information and 
applied to data collected in children to estimate the effects of pediatric specific covariates, in this 
case maturation and size. 
An improved understanding of the disposition of enterally dosed morphine gives us the 
ability to simulate concentration – time profiles by varying dosing regimens in neonates with 








The Potential for Personalized Medicine in Maternal Opiate Dependence  
and Neonatal Abstinence Syndrome 
 
Introduction 
Opiate dependent pregnant women around the world are treated with opiate maintenance 
medications to prevent illicit use and withdrawal during pregnancy. Fetal exposure to opiates 
causes central nervous system alterations which manifest as physical withdrawal after birth. The 
extensive variability in postnatal withdrawal remains unexplained. Improved understanding of 
functionally significant allelic variants in pathways influencing placental opiate transfer during 
pregnancy can advance treatment of maternal opiate maintenance and lead to improved obstetric 
and perinatal care. 
Background 
Neonatal Abstinence Syndrome (NAS) is the physical manifestation of opiate 
dependence in a newborn who was chronically exposed to opiates during gestation via maternal 
use. Infants at risk for NAS must be monitored in the inpatient setting after birth, and a fraction 
require prolonged hospitalization for pharmacologic therapy and weaning. The most severely 
affected infants cannot orally feed, fail to gain weight, and have seizure activity related to opiate 
withdrawal. There is also long-term neurodevelopmental morbidity associated with in utero 
opiate exposure. When compared to controls, children who were in utero opiate exposed have 
deficits in language, motor and cognitive development64. 
The current standard of care for pregnant women with opiate addiction or dependence is 
not to attempt to wean them off their medications or illicit drugs, but instead to provide excellent 
prenatal care with the adjunct of a maintenance opiate program. The two maintenance 
medications most commonly used are methadone and buprenorphine. According to the Substance 
Abuse and Mental Health Services Administration, there were 1,739 programs in the United 
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States offering addiction treatment to pregnant women in 2011, comprising 12.7% of all 
treatment programs. There are no current data about absolute numbers of pregnant women 
admitted to methadone and buprenorphine treatment programs, but around 20% of pregnant 
women admitted to drug treatment programs report opiates as their primary substance of abuse65. 
There have been many attempts to correlate maternal exposure, as measured by dose, to neonatal 
outcomes. A recent systematic review confirms the results of many smaller studies, namely that 
there is no currently known relationship between the maternal dose of methadone and the 
incidence or severity of NAS66. This lack of association is likely because our current thinking on 
the maternal – fetal – neonatal transfer and effect of opiate medications is oversimplified and 
does not account for the potential impact of pharmacokinetics, pharmacodynamics and 
pharmacogenetics and how these are affected by gestational changes in maternal physiology. In 
alternate terms, a central issue is the lack of knowledge to explain the relationship between 
maternal dose and systemic fetal exposure at the level of the individual mother-infant dyad. 
During pregnancy, opiate drugs available in the maternal system are passed to the fetus 
via the placenta, and drugs are actively effluxed back into the maternal circulation via transport 
proteins that are in both the basaolateral and apical sides of the syncytiotrophoblasts. In a small 
cohort of chronically treated women, the cord to maternal ratio at birth is 0.41 (range 0.19-0.56) 
for (R)-methadone and 0.35 (range .014-0.47) for buprenorphine67. There are potential 
pharmacologic factors that could affect the amount of free drug in the maternal circulation 
available for fetal transfer at any given time. The factors include both physiologic changes in drug 
disposition during gestation and genetic variability in key maternal drug metabolizing pathways, 




In addition to changes in maternal drug metabolism, the pumping efficiency of placental 
transport proteins such as Multi-drug Resistant Protein 1 (MDR1)**1 and Breast Cancer 
Resistance Protein (BCRP) could alter the ratio of maternal to fetal drug exposures. Lastly, fetal 
characteristics, such as efficiency of drug metabolism and mu-opioid receptor sensitivity and 
function might alter the infant’s development of NAS given the exposure to maternal 
medications. In addition to gestational and ontogenic changes in these pharmacologic factors, 
genetic variation potentially adds a layer of complexity to placental opiate transfer (Figure 11). 
The aim of this article is to review the pertinent literature addressing the effects of changing 
physiology during pregnancy and pharmacogenetic variation as sources of inter-individual 
variation in the extent and consequences of fetal/newborn exposure to opiates following maternal 
administration during pregnancy. This chapter will focus on pathways affecting opiate 
metabolism, opiate placental transport, and opiate receptor interactions. Data will be discussed as 
they pertain to the potential impact on our understanding and treatment of opiate dependence in 







                                                          
1 **The ABCB1 gene encodes Multi-Drug Resistant Protein 1, otherwise known as Permeable-
glycoprotein (P-gp). For the purpose of this review article, we will refer to the official gene name 




































Methadone is primarily N-demethylated to 2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolidine 
(EDDP) in the liver, predominantly by CYP2B668.  There are studies which show large 
interindividual variability in methadone pharmacokinetics. A study in peripartum women treated 
with methadone has shown no correlation between dose and plasma methadone concentrations69. 
There is evidence that a portion of this variability can be attributed to allelic variation in drug 
metabolizing enzymes. 
In vitro studies have assessed altered enzyme function leading to changes in metabolite 
formation as compared to wild type enzymes.  In human liver microsomes, N-demethylation of 
methadone by variant CYP2B6 enzymes is reduced to 25-33% of the wild-type enzyme.70 In 
addition, CYP2B6 genetic variants preferentially metabolize the S-methadone enantiomer71, 
resulting in a net reduction of R-methadone N-demethylation and different enantiomers of 
methadone may have differential placental transport. 
A human study has shown that haplotype blocks describing commonly co-occuring 
CYP2B6 single nucleotide polymorphisms (SNPs) in both intronic and exonic regions are 
predictive of plasma concentrations of methadone and the concentration to dose ratio in 366 
patients undergoing chronic methadone maintenance therapy72. A re-analysis of phenotypic 
extremes in a different cohort of methadone maintenance patients has shown that certain CYP2B6 
SNPs are more or less common in patients with high and low methadone concentrations, 
strengthening the etiologic link between genetic changes in the metabolizing enzyme and 
differences in methadone plasma concentrations73. In a systematic review, it was shown that 
patients homozygous for the CYP2B6*6 allele have higher trough (R) and (S) methadone plasma 
concentrations, suggesting that methadone metabolism is significantly slower in *6 homozygous 
carriers74.  Genetic polymorphisms in CYP2B6 are potential predictors of methadone clearance 
and concentrations and could prospectively be used to understand which fetuses are going to be 




Oxycodone is metabolized to oxymorphone, its active metabolite, by CYP2D6. There are 
four phenotypic groups based on CYP2D6 activity: poor metabolizers (PM), intermediate 
metabolizers (IM), extensive metabolizers (EM) and ultrarapid metabolizers (UM). Ratios of 
oxymorphone to oxycodone significantly differ by metabolizing enzyme genotype in 121 adult 
post-operative patients and PMs had the highest oxycodone consumption, suggesting a clinical 
consequence of poor metabolism to the active form of the drug75. Differential metabolism to 
oxymorphone in the maternal system can alter the concentrations of active metabolite available 
for placental transfer. 
Placental Transport of Drugs 
The placenta is a major line of defense for the developing fetus against pathogens and 
potentially harmful endogenous and exogenous substances in the maternal system. Placental 
transporters are known to modulate fetal exposure to maternal medications and other 
environmental exposures. Multi drug resistant (MDR1), also known as P-glycoprotein (P-gp) is 
encoded by ABCB1. Breast cancer resistance protein (BCRP) is encoded by ABCG2. Both of 
these transporters are part of a larger subgroup of ATP binding cassette (ABC) transporters 
known to control efflux of drug across the placenta. There are comprehensive reviews about 
transporters and the palcenta76-79, but the breadth and scope of their content are beyond the 
focused discussion of the studies in vitro, in animal models and in human placenta which confirm 
the role of these transporters is modulating drug concentrations between the maternal and fetal 
circulations, and the genetic variation which effect their function in regard to Neonatal 
Abstinence Syndrome. 
In vitro studies have shown that inhibitors of normal transport protein function increase 
drug concentrations in fetal circulation as compared to controls. Type II diabetes medications 
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have been studied extensively given the risk of hypoglycemia in the fetus. BCRP is postulated to 
play a role in effluxing glyburide at the apical membrane of the syncytiotrophoblasts, thus 
protecting the fetus from hypoglycemia. In a dual perfusion placental model, a BRCP inhibitor 
caused an almost doubling of the fetal-to-maternal concentration ratio of glyburide (0.56 +/- 0.06 
for inhibitor treated perfusions vs. 0.32 +/- 0.06, p-value 0.04)80. In cell lines over expressing 
BCRP, addition of transport protein inhibitors increased the intracellular concentrations 
(analogous with fetal circulation) of glyburide 3-fold81. Outside of the realm of diabetes therapy, 
antibodies against P-gp in monolayer cell culture dual chamber experiments increased the 
basolateral (fetal) concentrations of drugs such as dexamethasone and ritoniavir by as much as 
two fold compared with baseline levels82.   
Animal studies have confirmed the importance of P-gp in protecting the fetus in vivo 
from exogenous substances. In an experiment where multiple fetal genotypes were created in the 
same mother by mating males and females heterozygous for the MDR1a/1b genes which encode 
P-gp, IV drugs were administered to the pregnant mice and the fetal mice were sacrificed and 
labeled drug was quantified in the fetal plasma at various time points after maternal dosing83. For 
digoxin, saquinivir and paclitaxel, the fetal-to-maternal plasma concentration ratios were 
significantly higher for the P-gp deficient fetal mice (Figure 1). In addition, this group dosed the 
dams with enteral P-gp inhibitors and found that they could increase fetal concentrations of 
saquinivir by up to 7-fold. This study showed that presence or absence of functional P-gp can 




Figure 12: Ratio of fetal concentration to maternal plasma concentrations.  
Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH. Absence or pharmacological 
blocking of placental P-glycoprotein profoundly increases fetal drug exposure. The Journal of 
Clinical Investigation. Nov 1999;104(10):1441-1447. *copyright request granted 
 
CF-1 mice strains contain a spontaneous mutation in the mdr1a gene, leaving them P-gp 
deficient in multiple organs, including the placenta. In a study of these mice, males and females 
were selectively mated to create a range of litter genotypes including P-gp homozygote normal, 
heterozygote and homozygote null. The dams were treated with a radiolabeled toxin known to 
induce cleft palate and the neonatal mice were examined for birth defects (see Table 7) and have 
drug concentrations measured at birth. Zero percent of homozygous normal mice had cleft palate 
but 30% of heterozygous and 100% of homozygous null mice had cleft palate, showing a gene-
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dose effect for the role of P-gp in protecting fetal mice from this teratogen. Correspondingly, 
neonatal levels of toxin were 87-112, 124-180, and 542-678 pmol/g in the aforementioned 
genotypic groups84. 
 
Table 7: Incidence of cleft palate by fetus and litter according to genotype based mating pairs. 
Lankas GR, Wise LD, Cartwright ME, Pippert T, Umbenhauer DR. Placental P-glycoprotein 
deficiency enhances susceptibility to chemically induced birth defects in mice. Reproductive 




In addition to the known drug transporting properties, the ontogeny of placental 
transporters has been investigated using human placental tissue. In a study of homogenized 
placental tissue comparing 13-14 weeks via chorionic villus sampling and 38-41 weeks via 
vaginal and c-section deliveries, it was shown that the density of P-gp as measured by western 
blot was twice as high in early placentas as compared to late (p-value 0.0004)85. A second study 
confirmed these findings by comparing ABCB1 mRNA levels and P-gp expression by western 
blot between 6-13 week placentas from therapeutic terminations, 24-35 week placentas from 
preterm births and term placentas. Results (seen in Figure 13) show that there is statistically 




Figure 13:  MDR-1 mRNA in Human Placenta 
Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W. Expression of the multidrug 
resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with 
advancing gestation. Placenta. Jun-Jul 2006;27(6-7):602-609. *copyright request granted 
 
 
Placental Metabolism and Transport of Opiates 
Due largely to the work of the Obstetric-Fetal Pharmacology Research Unit  at University 
of Texas, we have in vivo and in vitro data of placental opiate metabolism and transfer. Key 
findings from various studies in these realms are summarized and synthesized in the following 
sections. 
Placental Opiate Metabolism 
Studies in placental microsomal preparation have given insight into the placental 
metabolism of methadone both in preterm87 and term placentas88. Using placentas from term 
healthy pregnancies, microsomal fractions of trophoblast tissue were studied using selective 
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inhibitors for different metabolizing enzymes and measuring biotransformation of methadone to 
EDDP. CYP19 / aromatase chemical inhibitors and neutralizing monoclonal antibodies were 
found to have the most profound effect on methadone metabolism, with 70-88% reduction in 
EDDP formation. The apparent Km and Vmax values are summarized in Table 8. Furthering this 
work by investigating placentas from earlier in gestation, late second trimester, early third 
trimester and late third trimester placental tissue was similarly used to measure enzyme kinetics. 
The apparent Km values for the different gestations were similar (Table 8) but the metabolism 
potential increased with gestation showing a statistically significant doubling of intrinsic 
clearance between late second trimester and late third trimester. In addition, there was marked 
interindividual variability in metabolizing enzyme activity even within the same gestational ages, 
four to six fold, suggesting that aromatase function could be one of the important factors in fetal 
exposure to active methadone and resultant NAS development. 
Buprenorphine is also metabolized by CYP19 / aromatase in the placenta89 and, similar to 
methadone, placental microsome studies have confirmed that enzyme activity in 
biotransformation of buprenorphine to norbuprenorphine (norBUP) increases with gestational 









Table 8: Placental Opiate Metabolism Table (compiled from multiple publications) Experimental 
model is microsomal fraction of trophoblasts for all experiments represented. 
 
Placental Opiate Transport 
P-gp is a known transporter for methadone. Using a single layer of syncytiotrophoblasts 
lineage cells in a dual perfusion model, Nanovskaya and colleagues showed that methadone 
transfer to the fetal circuit was increased by 30% by different P-gp inhibitors91. The authors 
concluded based on this experiment that the concentration of methadone in the fetal circulation is 
likely affected by the expression and activity of P-gp. 
From ex vivo experiments in a dually perfused placental model, it appears that 
buprenorphine transport across the placenta is not mediated by P-gp92, but rather via passive 
diffusion. Buprenorphine crosses placental cells into the fetal circuit less than methadone, with 
only 8.6 +/- 1.3% of initial maternal circuit concentrations detected in the fetal circuit after a four 
hour equilibration93. This decreased transfer of buprenorphine is thought to be secondary to its 





Methadone CYP19/aromatase  Term (?) 424 +/- 92 420 +/- 89 Nanovskaya 
2004  
 




192 +/- 88 Hieronymus 
2006  
 




271 +/- 88  
 
 




385 +/-129  
 
 
Buprenorphine CYP19/aromatase  Term (n=6) 13 +/- 4 2.9 +/- 0.7 Deshmukh 
2003  
 
Buprenorphine CYP19/aromatase  17-26 wks  
(n=7) 
15+/- 9 1.9 +/- 0.4 Fokina  
2011  
 
   27-33 wks 
(n=17) 







  34-37 wks 
 (n=6) 
24 +/- 8 2.8 +/- 0.7  
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highly lipophilic nature and significant tissue accumulation within the placenta as compared to 
both the maternal and fetal compartments. These ex vivo studies assess short time frames of 
placental pharmacokinetics and the applicability to chronic buprenorphine dosing in human 
pregnancies may not follow similar patterns. 
In addition to ontogenic changes discussed prior, evidence suggests that placental 
transporter expression can by induced by exposure to certain illicit substances, potentially 
impacting the maternal-fetal balance of methadone. In 24 term placentas tested in a dual 
perfusion model, experiments showed that the addition of methadone to control medium 
significantly increased the expression of P-gp (as measured by western blot analysis) by 49 +/- 
41% (p-value 0.03). Addition of cocaine and methadone, or heroine and methadone, increased the 
P-gp expression by 75 +/- 63% (p-value 0.01) and 59 +/- 51% (p-value 0.03) respectively94. 
Given that P-gp is known to transport methadone, this ex vivo evidence suggests that methadone 
induces P-gp expression, potentially adding to the mechanisms of protecting the fetus from high 
opiate exposures. 
Genetic Alterations in Placental Transport 
ABCB1 (P-gp) 
There is known genetic variation in  the ABCB1 gene which encodes P-gp. Among 
various different populations, the most common single nucleotide polymorphisms in ABCB1 are 
1236C>T (synonymous), 2677G>T/A/C (non-synonymous) and 3435C>T (synonymous). The 
non-synonymous 2677G>T linked in combination with 1236C>T and 3435C>T (MDR1*2) 
occurs in 62% of European Americans and 13% of African Americans and is shown to have 
enhanced in vivo P-gp activity, with the AUC for a prototype drug in non-pregnant humans being 
40% greater in MDR1*1 homozygotes as compared to MDR1*2 homozygotes with heterozygotes 
having intermediate values95.  
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Human placental in vitro studies into the effects of genetic variation are many and have 
shown that genetic polymorphisms in genes which encode placental transporters have an effect on 
mRNA and protein expression and activity96,97.  The biggest concerns in the field is the generally 
small number of placentas under study, the substrate specific effects of genetic changes and the 
inability to fully control for environmental factors which can alter transporter expression and 
function. A recent comprehensive review of the genetic implications for placental transport by 
Dr. Daud and colleagues proposes grouping the SNPs in placental proteins by similar functional 
in vitro effect or suspected phenotype in order to move from individual allele frequency analysis 
to cumulative phenotype frequency analysis98. The potential for fetal teratogenicity has been 
studied in mothers carrying the MDR1 3435C>T SNP and there is increased risk of cleft lip and 
palate99 and congenital heart disease100 in mothers with the minor allele. 
ABCG2 (BCRP) 
Common SNPs in ABCG2 include 421C>A, 34G>A and 376C>T. One study in human 
placentas showed that homozygotes for the A421 allele had significantly lower protein levels than 
those for the C421 allele and heterozygotes had intermediate values101. The clinical implications 
of SNPs in ABCG2 have not yet been investigated in pregnancy. 
Neonatal Metabolism and Drug Effector Compartment 
The current standard therapy for moderate to severe NAS revolves around opiate 
replacement therapy post-natally. The two most commonly used opiates are enteral morphine and 
enteral methadone solutions. Between the years 2004 to 2011, morphine was used as first line 
therapy in 49-53% of 14 large US hospitals and methadone used as first line therapy declined 
from 44% to 11%102. Genetic modifiers to morphine metabolism include polymorphisms in both 
OCT1, a gene which encodes a liver transporter, and UGT2B7, the enzyme responsible for 
morphine glucuronidation. For methadone, SNPs in CYP2B6 are known to correlate to clearance 
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of methadone in adults. In addition to genetic modifiers of the pharmacokinetics, data suggests 
that polymorphisms in the mu-opiate receptor (MOR1) can have clinically important implications 
in response to opiate treatment for pain and these same SNPs may play a role in an infant’s 
clinical response to morphine or methadone therapy for NAS. 
Neonatal Opiate Disposition 
In order for morphine to be metabolized and cleared, it must first be transported from the 
plasma to the hepatocyte and then metabolized via glucuronidation. OCT1 facilitates hepatic 
morphine uptake103. In humans, carriers of a loss of function allele in OCT1 had a mean AUC of 
morphine 56% higher than non-carriers103.  Race appears to correlate with clinical response to 
morphine for pain, adverse events and morphine clearance104. Because this correlation is not fully 
explained by SNPs in drug metabolizing enzymes, liver uptake proteins including OCT1 are 
being investigated. Morphine clearance was compared among146 post-operative children, 
stratified by haplotype for loss-of-function OCT1 variants. Using population modeling and post 
hoc Bayesian estimates, morphine clearance was 17% lower in homozygotes for loss-of-function 
alleles105. In this population, it was confirmed that the genetic contribution of UGT2B7 -900A>G 
to morphine clearance was low compared to the contribution of OCT1 genetic variability. The 
OCT1 transporter may not only affect PK of postnatally administered opiates, but also the 
clearance of maternally acquired drug in the first few days after delivery. The rapidity of 
clearance of maternally acquired opiate may impact onset and severity of NAS symptoms. 
Neonatal Drug Effector Compartment 
In addition to the genetic influences on PK, an important aspect of response to clinical 
treatment with morphine is the effector site. For NAS, this involves opiate moving across the 
blood brain barrier (BBB) and acting upon the opiate receptor. ABCB1 encodes the BBB 
transporter P-glycoprotein. There is animal data linking genetic variation in this gene to opiate 
68 
 
induced hyperalgesia, tolerance and dependence106. The observations in this mouse study were 
especially powerful because the investigators were able to measure opiate concentrations in the 
brain and further validate the underlying physiology of genetic modifiers of BBB transport 
function. In human adults, SNPs in ABCB1 are correlated with need for rescue medication in 
chronic pain therapy107 and opiate consumption in immediate post-operative pain108. 
OPRM1 encodes the mu-opioid receptor 1 which is the main receptor target for morphine 
therapy in NAS. The OPRM1 118A.G SNP is associated with less need for pharmacologic 
therapy and shorter length of treatment in infants with in utero acquired NAS109. Although data 
about MOR1 genetic variability in NAS limited, extensive recent literature in adults shows that 
common variants in OPRM1 are associated with post-op opiate response to pain110-112 clinical 
severity of opiate drug overdose113,114 and tolerance to experimentally induced pain115. Given a 
similar receptor target for pain treatment and NAS treatment, suffice to say that genetic 
variability in OPRM1 may contribute to clinical response to opiate therapy for NAS and that this 
is a field which requires further study. 
Combination genotypes on ABCB1 and OPRM1 (i.e. wild type for both vs. mutant for 
either or both) are associated with oxycodone clinical effects and adverse drug reactions in adult 
humans. In addition to single gene effects, the combination effect of genetic variability in BBB 
transport and opiate receptor function may be synergistic or additive in clinical response to 
treatment of NAS.  
Summary 
In summary, there are knowledge gaps in maternal opiate maintenance therapy and fetal 
opiate exposure. If we can more fully understand how maternal dose relates to maternal exposure, 
how the placenta regulates the maternal exposure to the fetus, and how the fetus and neonate are 
variable in their pharmacodynamic effects, therapy for these mother-infant dyads could be more 
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tailored than current.  For example, the gestational changes in drug metabolizing enzyme function 
are not adequately understood. Although there are current PBPK models for pregnant women, 
certain enzymatic pathways require more data to understand the complete picture of drug 
disposition. The interplay of relative upregulation and downregulation of multiple hepatic 
elimination pathways, and how these interact with increased renal clearance must be taken into 
account. Secondly, we need further research to understand the influence of genetic variants on 
placental transporter and enzyme expression and function with regards to fetal opiate exposure. It 
is possible that with improved knowledge of genotype-phenotype correlation, the most at risk 
fetuses could be identified prenatally and appropriate maternal medication adjustments could be 
made. Lastly, interindividual variability in response to postnatal treatment is multifactorial. The 
severity of in utero dependence, neonatal opiate disposition, the dynamic postnatal clearance and 
pharmacodynamic effect all play a role in an individual infant’s clearance of maternal medication 
and response to postnatal opiate therapy. As discussed in a recent commentary116 on changes in 
drug disposition during pregnancy, the most promising path forward is to integrate findings from 
in vitro studies, animal studies, and in vivo human clinical studies to create a more complete 
understanding of maternal disposition and fetal exposure (Figure 3). 
Neonatal Abstinence Syndrome carries long term morbidity, and the current empiric 
approaches used to choose maternal drug and dose, decisions to wean, identifying the infants 
most at risk, and postnatal treatment paradigms could all use improvements towards more 
personalized therapies in order to potentially mitigate these morbidities. A recent article compares 
the early neurodevelopmental outcomes of infants exposed to heroine, methadone and other 
opiates in utero with age matched Bayley-III standard controls. Mean scores for language (82.12 
vs. 100), motor (96.25 vs. 100) and cognition (90.18 vs. 100) were all statistically significantly 
lower in the opiate exposed group64. In addition, infants exposed prenatally to opiates are shown 









 This thesis encompasses three studies, all of which further out understanding of neonatal 
opiate exposure and treatment. Medical opiate exposure and resultant NAS are increasing, and the 
awareness of this will lead neonatologists to reconsider pain and sedation protocols and consider 
standardized approaches to escalation and weaning of opiates in the NICU. Building upon prior 
knowledge, we have shown that enteral morphine is 59% bioavailable in a cohort of infants with 
NAS, the first step in future drug simulation studies aimed at optimizing opiate dosing for NAS. 
Lastly, the current knowledge as it pertains to the potential for genetic variability to influence 
placental opiate transfer is reviewed. A deeper understanding of these intricate processes will aid 
in design of studies aimed at personalizing care for maternal opiate dependence and resultant 
Neonatal Abstinence Syndrome. 
 Neonates are considered an “orphan population” by many in pharmacology and drug 
development. These three bodies of work are the preliminary knowledge for the promise of future 
research. Drug prescription monitoring will continue to shed light on the pharmacoepidemiology 
of neonatal drug exposure. Elegantly designed studies with sparse sampling and advanced 
modeling techniques, maximizing use of prior data, can expand the pharmacokinetics and 
pharmacodynamics knowledge base of current and future drugs in neonates. And lastly, in order 
to keep up with the rapidly evolving pace of modern medicine, pharmacogenetic underpinnings of 
variability in placental opiate transfer holds the promise of individualizing the approach to 
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JHM IRB - eForm A – Protocol  
 Use the section headings to write the JHM IRB eForm A, inserting the appropriate 
material in each. If a section is not applicable, leave heading in and insert N/A. 
 When submitting JHM IRB eForm A (new or revised), enter the date submitted to the 




a. Provide no more than a one page research abstract briefly stating the problem, the 
research hypothesis, and the importance of the research. 
 
Neonatal abstinence syndrome (NAS), the syndrome of narcotic withdrawal in neonates 
has been well studied1. NAS can be the results of either discontinuation of narcotic exposure 
when an infant is born to a drug-abusing mother or the discontinuation of narcotic in the 
medical setting after need for narcotic therapy in the management of pain and sedation. 
Symptoms of NAS include tremors, irritability, vomiting, trouble sleeping, incessant crying, 
problems feeding and other behavioral disturbances.  Although NAS is a predictable side effect 
of narcotic use in the ICU setting, recently practitioners have begun to realize its true impact on 
hospital length of stay. There is an increasing effort to document iatrogenically induced 
Neonatal Abstinence Syndrome (NAS) when narcotics are used by health practitioners for pain 
control and sedation. 
The hypothesis of this study is that infants born in fiscal year 2011 with the same 
primary diagnoses have greater exposure to narcotics and that the duration of treatment of 
iatrogenic NAS is longer in more recent years. It is also hypothesized that there is a duration or 
cumulative dose of narcotic that predicts iatrogenic NAS, which would be different for 
premature and mature infants.  
This study will give health practitioners a better understanding of the trends in infant 
exposure to narcotics and iatrogenic NAS over time, and will bring the need for more in depth 
study of optimizing prevention and treatment for iatrogenic NAS to attention among 
researchers in pediatrics and neonatology.  
In determining the duration or cumulative dose of narcotic that predicts iatrogenic NAS, 
this study can serve as an initial guide for health practitioners in maximizing the benefits of 




2. Objectives (include all primary and secondary objectives) 
 
Specific Aim 1: Compare cumulative exposure of narcotic (by measures such as 
cumulative dose or duration, mean mg per day of admission) between 3 time epochs: 
fiscal year (FY) 2004, FY 2008 and FY 2011 in the Johns Hopkins NICU and PICU. 
Hypothesis: After controlling for confounding factors related to narcotic exposure, 
infants born in 2011 will have greater cumulative exposure to narcotics as part of ICU 
care.  
Specific Aim 2:  Describe trends in the incidence of iatrogenic NAS over time. 
Hypothesis: Because of increasing exposure to narcotics over time, infants born in the 
latter time strata are more likely to experience iatrogenic NAS. 
Specific Aim 3: Identify a critical cumulative narcotic exposure that predicts well a 
diagnosis of NAS in a majority of infants. Hypothesis: The predictor of five days of 
narcotic exposure as predictive of NAS currently in the literature2 is accurate.  
3. Background (briefly describe pre-clinical and clinical data, current experience with 
procedures, drug or device, and any other relevant information to justify the research) 
 
There is a general sense among practitioners that the therapeutic use of 
narcotics in neonates has been increasing over time. To our knowledge, there has been 
no study assessing the trends over time in neonatal narcotic exposure in the Intensive 
Care Unit. While there have been studies showing infants exposed to more than five 
days of continuous narcotics are at increased risk of NAS2, other factors such as 
gestational age and cumulative dose may also contribute to their responses. Our 
research team has approached the neonatal pharmacist Carol Wesolowski to consult 
with her about the best possible way to capture total narcotic exposure and she 
recommends a combination of hand calculation from orders in the chart and then 
secondary confirmation of narcotic exposure via pharmacy records of narcotic doses 
dispensed. She has confirmed that the electronic pharmacy records go back beyond FY 
2004 and can be queried by patient medical record number. 
Our research team has consulted with the department of Pediatric Billing 
located at the Johns Hopkins White Marsh location and have developed a search 
strategy to successfully identify all infants with the diagnoses discussed via billing 
records. By fiscal year, they can query all billing records (including 
inpatient/outpatient/radiology/laboratory) for the top five billing diagnoses associated 
with a charge. They feel confident that through casting this wide net, we will be able to 
capture all infants admitted to Johns Hopkins Hospital with these diagnoses through 




Our research team (which includes neonatology, pharmacy, clinical 
pharmacology) has experience with retrospective chart review and calculation of 
cumulative narcotic exposure. Please see below for brief example.  
Retrospective chart review: Use of opioids for treatment of postoperative pain in 
neonates  
In order to determine the number and characteristics of potential subjects for a 
separate trial, we have retrospectively reviewed the charts of 23 consecutively admitted 
infants who were  ≥35 weeks at the time of surgery between the dates of 3/1/10-5/1/10 
(non-cardiac diagnosis) and 7/1/11-12/30/11 (cardiac diagnosis). We determined the 
cumulative opioid dosage (in morphine equivalents)  during the first 4 post-operative 
days, the duration of opioid therapy, the number of postoperative days before the start 
of enteral feeds, and the total number of  postoperative ventilator days.  All the cardiac 
and non-cardiac infants were managed in the PICU or NICU, respectively.  
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4. Study Procedures 
a. Study design, including the sequence and timing of study procedures   




This study will be a retrospective chart review of intants with diagnoses prone to 
high or prolonged narcotic exposure chosen from three time strata: fiscal years 
2004, 2008 and 2011. These diagnoses will include 1) hypoplastic left heart/double 
outlet right ventricle, 2) congenital diaphragmatic hernia, 3) meconium aspiration 
syndrome/persistent pulmonary hypertension of the newborn, 4) 
gastroschesis/omphalocele and 5) extreme prematurity (born at less than or equal 
to 25 weeks completed gestation).  
These infants will be identified via billing records and once the infant is deemed 
eligible via bried NICU/PICU discharge summary review (look at diagnoses listed, 
surgical procedures and length of stay), a more extensive chart review will be 
conducted (see below). 
For each infant, the chart will be reviewed and the following data will be collected: 
Demographic data: medical record, date of birth, gender, race, gestational age at 
birth, date of admission, date of discharge 
1. primary clinical diagnosis requiring ICU admission 
2.  total duration of narcotic therapy 
3. cumulative narcotic dose in milligramsof morphine equivalents 
 Equations for conversion to morphine equivalents: 
  1 mcg/kg fentanyl equivalent to 20 mcg/kg morphine 
1 mcg/kg dilaudid equivalent to 5 mcg/kg morphine  
1 mg methadone equivalent to 10 mg morphine 
4. Diagnosis of NAS in chart (yes/no) 
5. Did infant need slow wean of narcotic therapy although never diagnosed with 
NAS officially? 
6. Confounder variables collected which would affect the estimate of association 
between year of admission and narcotic exposure: 
 a. SNAP-II score3:every infant will have a disease severity score calculated 1) at 
12 hours of life and 2) on the day that narcotic therapy was initiated. This severity 
score will be accounted for in the analysis of narcotic exposure 
 b. Other major medical diagnoses (resp,CV,GI) 
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 c. All surgical proecedures 
 d. Infant exposed to paralytic (Yes/No) 
 e. Length of stay (cumulative narcotic exposure will be standardized by length of 
stay for certain parts of the analysis). 
7. Was infant exposed to benzo and what was total benzo dose? 
8. Time from start of narcotic to extubation 
9. Time from start of narcotic to full enteral feeding (off IV nutrition) 
10. Number of days on antibiotic therapy (this will be used as an overall measure of 
“intensive care” – i.e. a control measure to compare the increasing narcotic 
exposure. For example, if someone wonders if narcotic exposure is increasing 
because overall intensity of ICU care is increasing, we will have antibiotic exposure 
as a comparison “control” outcome. 
b. Study duration and number of study visits required of research participants. N/A 
c. Blinding, including justification for blinding or not blinding the trial, if applicable. 
N/A 
d. Justification of why participants will not receive routine care or will have current 
therapy stopped. N/A 
e. Justification for inclusion of a placebo or non-treatment group. N/A 
f. Definition of treatment failure or participant removal criteria. N/A 
g. Description of what happens to participants receiving therapy when study ends or if 
a participant’s participation in the study ends prematurely. N/A 
 
5. Inclusion/Exclusion Criteria Infants will be included if they are identified through billing 
records as having been at JHH NICU/PICU during the above-mentioned fiscal years and 
they carry one of the five diagnoses: 1) hypoplastic left heart/double outlet right 
ventricle, 2) congenital diaphragmatic hernia, 3) meconium aspiration 
syndrome/persistent pulmonary hypertension of the newborn, 4) 
gastroschesis/omphalocele and 5) extreme prematurity (born at less than or equal to 
25 weeks completed gestation). Infants will be excluded if they were not born at Johns 
Hopkins or if they were transferred to another facility before narcotic therapy was 
stopped. 
 
6. Drugs/ Substances/ Devices N/A 
a. The rationale for choosing the drug and dose or for choosing the device to be used. 
N/A 
b. Justification and safety information if FDA approved drugs will be administered for 
non-FDA approved indications or if doses or routes of administration or participant 
populations are changed. N/A 
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c. Justification and safety information if non-FDA approved drugs without an IND will 
be administered.  N/A 
 
7. Study Statistics 
a. Primary outcome variable: cumulative narcotic exposure in mg of morphine 
equivalents (this will be modeled as a continuous outcome) 
b. Secondary outcome variables: length of therapy with narcotics, length of 
hospitalization, time to full enteral feeds, time to extubation 
c. Statistical plan including sample size justification and interim data analysis. From 
preliminary billing data, we estimate that we will have 40 infants per year that fulfill 
the inclusion criteria listed above (majority are meconium aspiration/PPHN and 
primary cardiac diagnoses). 
d. Power analysis: With 10 patients in each time strata for a certain primary 
diagnosis, we will have an 88% power to predict a 20% change in narcotic 
exposure using a significance value of .05. (Used for power calculation: Average 
narcotic exposure 100 mg morphine equivalents, standard deviation 20 mg). 
e. The exposure of time will be modeled as disjoint categories by year strata and 
we will use linear regression to model narcotic exposure, controlling for 
covariates discussed above. A type-1 error cutoff of .05 will be used for 
statistical significance.  
f. For comparing incidence of NAS in the three strata, we will use analysis of 
variance techniques to compare the groups, also considering a type-1 error 
cutoff of .05 for statistical significance. 
g. Early stopping rules. N/A 
 
8. Risks 
a. Medical risks, listing all procedures, their major and minor risks and expected 
frequency. N/A 
b. Steps taken to minimize the risks. N/A 
c. Plan for reporting unanticipated problems or study deviations. N/A 
d. Legal risks such as the risks that would be associated with breach of confidentiality. 
All data will be de-identified in the study database with a master file linking patient 
ID to study number kept locked in the PI office. All members of the study will be 
thoroughly trained in HIPAA compliance and data management.  
e. Financial risks to the participants. N/A 
 
9. Benefits 
a. Description of the probable benefits for the participant and for society. 
This study will give health practitioners a better understanding of the trends in 
infant exposure to narcotics and iatrogenic NAS, and its possible correlation 




In determining the duration or cumulative dose that predicts iatrogenic NAS, 
this study can serve as a guide for health practitioners in maximizing the 
benefits of hospital use of narcotics and minimizing its associated risks.  
 
10. Payment and Remuneration 
a. Detail compensation for participants including possible total compensation, 
proposed bonus, and any proposed reductions or penalties for not completing 
the protocol. N/A 
 
11. Costs 
a. Detail costs of study procedure(s) or drug (s) or substance(s) to participants and 
identify who will pay for them. N/A 
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a. Provide no more than a one page research abstract briefly stating the problem, the 
research hypothesis, and the importance of the research. 
 
Neonatal Abstinence Syndrome is a complex physiologic result of in utero or ex-utero 
iatrogenic exposure to opiate medications. The in utero exposure is a result of 
maternal use of opiates, usually methadone or heroine, during the pregnancy. The 
iatrogenic exposure is a result of medical treatment with opiates for the management 
of pain and sedation in the Neonatal and Pediatric Intensive Care Unit. The cellular 
mechanisms of analgesia, tolerance and dependence to opiates are increasingly clear, 
but the clinical management of Neonatal Abstinence Syndrome is yet imprecise. The 
goals of this research project include: SA1 To develop a population pharmacokinetic 
model for oral morphine and its glucuronide metabolites in neonates undergoing 
therapy for either ICU or in utero acquired Neonatal Abstinence Syndrome. These two 
cohorts will include 40 fullterm infants, each prospectively recruited at the time of 
treatment for Neonatal Abstinence Syndrome. SA2 To develop a population 
pharmacokinetic/pharmacodynamic model for the relationship between morphine and 
its metabolites with the clinical outcome of behavioral withdrawal scores. This model 
will allow a quantitative link between morphine, morphine metabolite serum 
concentrations and clinical symptoms of NAS. SA3 Compare the pharmacodynamic 
relationship from SA2 between two populations of infants with NAS – those in utero 
exposed and those ICU exposed in order to identify key differences in the morphine 
concentration – clinical outcomerelationship. Taking into account differences in the 
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pharmacologic relationships in the two populations, we will predict appropriate dosing 
regimens based on identified important clinical covariates for goal withdrawal scores 
during treatment of NAS. 
Relevance: Neonatal Abstinence Syndrome is a common and challenging clinical 
problem faced by pediatricians and neonatologists, and a disease which carries great 
morbidity for neonates. Understanding the pharmacologic mechanisms which underly 
therapy will greatly advance the field of opiate tolerance and withdrawal in this 
vulnerable population. 
2. Objectives (include all primary and secondary objectives) 
The response to morphine therapy for the management of pain and sedation during 
acute illness and the response to weaning of narcotics during detoxification is clinically 
variable and unpredictable in the neonatal population.  While biologic and genetic 
factors likely contribute to this response variability, little is known about factors that 
contribute to response variability to opiate detoxification in infants.  Infants are 
exposed to opiates either in uteri via maternal drug use, or during medical therapy in 
the intensive care units (ICU), and Neonatal Abstinence Syndrome (NAS) is a the 
manifestation of opiate withdrawal when these medications are weaned or 
discontinued. Heterogeneity in practice for treatment of NAS including starting doses, 
rapidity of escalation and de-escalation of opiates, and the duration of therapy lead to 
either unnecessary symptoms in infants, or unnecessary opiate exposure. The overall 
goal of this research is to better understand the physiology of Neonatal Abstinence 
Syndrome and to maximize medical therapy for NAS using a population pharmacology 
approach to describe the relationship between serum morphine and the clinical 
syndrome of NAS. 
 
Aim 1: Develop a population pharmacokinetic model to describe changes in parent 
drug: metabolite ratios for multiple metabolic pathways of morphine.  Prospectively 
collected morphine and glucuronide metabolite concentrations measured in serum 
samples from 40 ICU and 40 in utero exposed full term infants will be combined to 
model serum concentrations of these drugs based on important clinical covariates 
including postnatal age, gender, ventilation status and end organ function. This 
pharmacokinetic model will be used in S.A. #2 to make a clinically useful link between 
morphine dosing/metabolism and the clinical syndromes of NAS.  
 
Aim 2: Develop a population pharmacodynamic (PD) model describing the 
relationship between validated withdrawal scores (WS) for NAS and 
morphine/morphine metabolite concentrations in full term infants with NAS. To 
begin to explore factors that contribute to response variability during detoxification in 
hospitalized infants, we propose to determine the pharmacodynamic relationship 
between WS and serum morphine levels in two cohorts of infants who are undergoing 
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detoxification from opioids, either as a result of ICU exposure or maternal use during 
pregnancy. We hypothesize that changes in morphine metabolism with age and 
differences in end organ function will account for some of the interindividual variability 
in response to weaning of morphine during treatment for NAS.  
 
Aim 3: Compare the pharmacodynamic relationship between morphine and WS in 
two populations of infants undergoing treatment for NAS: those prenatally exposed 
and iatrogenically exposed.  Using “cohort status” as a covariate in the PK/PD model, 
we will investigate clinically meaningful differences in the morphine concentration – 
withdrawal score relationship which would warrant different dosing or treatment 
thresholds for the ICU population. We hypothesize that morphine concentrations and 
WS will have a different PD relationship in the prenatally exposed cohort than in the 
ICU cohort because infants in the ICU have complex illnesses that affects their 
pharmacologic response to morphine therapy.  
 
With the accomplishment of these three aims, we will gain a much greater 
understanding of oral morphine pharmacology in this complex population. The 
pharmacokinetic/pharmacodynamic properties which underlie current therapy for NAS 
will aid us in more rational dosing of morphine for NAS in sub-populations of infants, 
leading to more appropriate narcotic exposure, better control of symptoms and 
improved prognostic abilities regarding length of therapy.  In the future, these models 
could be prospectively validated and used to create guidelines which would globally 
impact the care of infants with NAS. 
 
3. Background(briefly describe pre-clinical and clinical data, current experience with 
procedures, drug or device, and any other relevant information to justify the research) 
 
Opiates are an integral part of Neonatal and Pediatric Intensive Care.  Pediatric and 
neonatal patients in the Intensive Care Unit are subject to multiple painful procedures 
and are at high risk for chronic discomfort from mechanical ventilation and indwelling 
catheters and other devices120; in addition their typical pain responses may be immature 
and lead to undertreatment121. The necessity of adequate analgesia came to the 
forefront in the 1970s and there are multiple reasons to treat pain including decreased 
stress response, decreased neuronal cell death, and improved clinical outcomes122.  
Opiates are the most commonly used analgesic in the ICU setting123. Multiple behavioral 
scales which incorporate both vital sign and clinical/physical data to measure pain in 




Opiate therapy leads to tolerance and physical dependence. Morphine is the most 
commonly used drug for analgesia in ventilated neonates126. Morphine  is a mu-opioid 
receptor agonist  and when given peripherally, the cumulative exposure at the effector 
site in the CSF is 18% that in the plasma in adults 127. Opiate induced hyperpolarization 
of the neuronal membrane leads to decreased neurotransmitter release leading to 
clinical analgesia and sedation. Therapy with morphine leads to tolerance and 
dependence in neonates.  Cellular mechanisms of tolerance and dependence include 
supersensitization of adenylyl cyclase and altered coupling of opiate receptors to 
excitatory g-proteins. Via protein kinase signaling systems, the duration of opiate 
receptor occupancy can influence opiate receptor internalization, down-regulation and 
desensitization128. Multiple predictors of the development of tolerance and dependence 
have been identified and include duration of therapy, continuous vs intermittent 
therapy and cumulative dosing. 
Morphine metabolism to M3G and M6G is developmentally variable Morphine is 
metabolized via hepatic enzyme UGT2B7 to morphine 3-glucuronide and morphine 6-
glucuronide, both of which are highly hydrophobic molecules. At birth, the median 
glucuronidation activity is low with a postmenstrual age and postnatal age-dependent 
increases to an adult levels129. Preterm neonates primarily metabolize to M3G which has 
anti-analgesic properties and this predisposes them to rapid morphine tolerance. 
The population pharmacokinetics of IV morphine has been studied in neonates and 
infants. The population pharmacokinetics of morphine and its metabolites have been 
modeled and validated in infants 130. Dr Knibbe and colleagues studied 248 infants and 
their resultant 2159 morphine and glucuronide concentrations to build a non-linear 
mixed effects population pharmacokinetic model. The formation and elimination 
clearance of the glucuronides were estimated and variation was found to be correlated 
with infant bodyweight. In addition, a postnatal age of 10 days was found to be 
associated with glucuronide formation clearance, independent of birthweight or 
postnatal age. Using this model, simulations were able to show that in newborns and 
infants less than three years old, a loading dose of 100 mcg/kg followed by a continuous 
infusion of 10 mcg/kg/hour resulted in a narrow and predictable range of serum 
morphine and metabolite concentrations. Developmental pharmacodynamics is the 
study of maturation of biologic systems and the changing drug-clinical target 
relationship. 
The population pharmacokinetic (morphine metabolism in the body) to 
pharmacodynamic (the clinical effect of morphine) link has not been explored in 
Neonatal Abstinence Syndrome. Neonatal Abstinence Syndrome (NAS) is prevalent in 
the NICU and PICU 124,131. There have been multiple validated withdrawal symptom 
scales published and they are routinely used for diagnosis and management of NAS 
which result from both in utero and ICU exposure to opiates. There are currently no 
studies that investigate the therapeutic serum concentrations of morphine and 
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metabolites which correspond to “well managed” NAS which could be defined as a 
threshold withdrawal score. There are many barriers to this type of research, but there 
are examples in the literature of important insight into PK/PD relationships using pain 
scales. 
Population pharmacodynamic models have been used successfully in adults to 
correlate drug data with clinical outcomes in adults and children. A population 
kinetic/dynamic model has been developed to investigate morphine titration in the 
immediate post-operative period using visual analog pain scales in adults. In this model, 
important clinical covariates predicting response to morphine therapy included 
decreasing delay between extubation and titration,  intra-operative NSAIDs, and 
decreasing initial postoperative pain132. Somma et al described the PD of midazolam 
using sedation scores and using mixed effect modeling, was able to predict the sedation 
score within 1 level with 83% accuracy133. Anderson et al used population 
pharmacodynamic modeling to recommend acetaminophen dosing guidelines post-
tonsillectomy, with a goal to achieve a visual analog pain score <4/10134. 
There are important clinical covariates unique to the neonatal ICU population which 
would need to be measured and accounted for in the PK/PD modeling of morphine for 
Neonatal Abstinence Syndrome. The most striking aspect of neonatal and pediatric 
PK/PD parameters is the rapid rate of change early in life secondary to changes in body 
composition, major organ function135, and in the case of CNS-active drugs, the 
maturation of the blood brain barrier and the neuronal connections and receptor 
density themselves 136. Parameters that have been previously considered in this realm of 
modeling include: postmenstrual age, postnatal age, weight. Given the correlation of 
age and weight attainment, pharmacologic models use allometric scaling methods to 
account for changes in weight with age in order to investigate other important 
covariates. In the ICU population, other important influences such as derangement in 
normal kidney (elimination) and hepatic (metabolism) function 137could influence the 
effect of morphine on NAS. Of note, it has been documented in both adults and 
neonates, mechanical ventilation can cause changes in hepatic blood flow and thus the 
rate of glucuronidation of certain drugs138. Unique to the pharmacodynamics of NAS 
include measures of previous narcotic exposure including cumulative dose and duration 
of therapy with opiates in the ICU exposed. 
It has been assumed that in utero acquired and ICU acquired NAS are the same 
biologic entity, thus they are measured and treated similarly. The medical literature 
includes a multitude of studies on the risk factors for, diagnosis, and treatment of in 
utero acquired NAS 139-142, but there has been little direct investigation of ICU acquired 
NAS and the majority of this limited research has been epidemiologic in nature143,144. 
There is clinical concern that the traditional signs and symptoms of NAS are altered in a 
medically labile population. Directly comparing the PD relationship between 
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morphine/morphine metabolites in these two cohorts will provide insight into any 
potential differences in the underlying pathophysiology. 
Pharmacodynamic modeling of morphine for NAS – what are the clinical implications? 
The current management NAS is imprecise and extremely variable regarding starting 
doses, titration methods and length of therapy. Understanding the pharmacodynamic 
link between morphine, morphine metabolites and clinical withdrawals scores would 
allow simulations based on patient characteristics to rationally dose and titrate 
morphine therapy for Neonatal Abstinence Syndrome. 
4. Study Procedures 
a. Study design, including the sequence and timing of study procedures 
(distinguish research procedures from those that are part of routine care). 
b. Study duration and number of study visits required of research participants. 
c. Blinding, including justification for blinding or not blinding the trial, if applicable. 
d. Justification of why participants will not receive routine care or will have current 
therapy stopped. 
e. Justification for inclusion of a placebo or non-treatment group. 
f. Definition of treatment failure or participant removal criteria. 
g. Description of what happens to participants receiving therapy when study ends or if 
a participant’s participation in the study ends prematurely. 
 
Overview: This is a prospective cohort study involving two groups of infants: a) fullterm 
well infants in the Newborn Nursery with Neonatal Abstinence Syndrome (NAS) 
acquired in utero  who are being treated with oral morphine, and b) fullterm infants less 
than 12 months old in the Neonatal Intensive Care Unit who are being treated with oral 
morphine for NAS acquired via iatrogenic exposure. Both cohorts will be identified via 
pharmacy prospective POE ordering of intermittent oral morphine. Blood samples will 
be collected to measure morphine, glucuronide metabolites of morphine, and sulfation 
metabolites of morphine – these will be used for the population pharmacokinetic 
analysis. Saliva samples will be collected, DNA extracted and SNP genotyping of three 
relevant genes performed and these SNP results will be used in the pharmacodynamics 
analysis. NAS scores will be extracted from the electronic record and used as the clinical 
outcome for the pharmacodynamic analysis. The PK/PD relationship of morphine for 
NAS will be compared between the two cohorts, and model based simulations will be 
used to recommend rational morphine dosing for NAS based on relevant clinical 
covariates identified is SA2 and SA3. 
Patient population: 
a) In utero cohort:  40 consecutive infants with a diagnosis of NAS secondary to in 
utero exposure to either methadone, heroine or both will be identified via 
automated oral morphine order entry recognition in POE.  The current standard of 
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care for NAS at the Johns Hopkins fullterm nursery is oral morphine,  So every infant 
with NAS would be eligible for the study. 
b) NICU cohort: Infants with NAS from iatrogenic exposure will be identified via  a 
screening process which includes: automated recognition of any POE order for “NAS 
scores” – these infants will be evaluated, and if they are receiving oral morphine for 
NAS, they will be eligible for the study cohort. We will limit to infants >35 weeks GA 
as this groups is the most likely to receive oral morphine as standard of care for 
NAS.  Infants >12 months postnatal age at time of eligibility will be excluded. 
-GA at birth will be defined by admission note to NICU, postnatal age will be calculated 
as number of days since birth 
-Exclusion criteria: Infants with major chromosomal anomalies (trisomies), infant with 
CNS disease which would make NAS scoring inaccurate (hypoxic ischemic 
encephalopathy, stroke, major brain malformation) will be excluded. 
NAS scoring: Infants at risk for NAS, either from in utero or iatrogenic exposure, receive 
every 4 hours Modified Finnegan scores 43and these are recorded in the electronic 
health record at the time of collection by a trained NICU/Newborn nursery RN. From the 
start of morphine therapy for NAS, all scores will be recorded for every enrolled infant in 
an electronic database which pulls the data directly from the patient record (this 
mechanism is already established for an ongoing clinical trial). The NAS scores will be 
collected until 48 hrs after morphine is discontinued or until infant is transferred to 
another facility. 
Blood sampling: In order to build a population pharmacokinetic model of oral 
morphine, blood samples will be collected for measurement of morphine and its 
metabolites.  Several reference papers have modeled the PK of IV morphine in the 
neonatal population and these are used to determine approximate sample sizes for 
morphine and morphine metabolite levels. 
Collection times after q3 or q4 morphine dose:  15, 30, 45, 60, 120, 180, 240 minutes 
post dose 
Newborn nursery:  40 infants, 4 samples collected per infant at any of the above times, 
12-18 samples at each of the above time points after combining data from all infants. -
These infants do not have routine blood draws, thus the 200 microliter samples will be 
collected via heelstick (3-4 drops) in capillary tubes, each on a separate treatment day to 
decrease risk of pain to participants. 
NICU population: 40 infants,  4samples collected per infant at any of the above times, 
12-18 samples at each of the above time points after combining data from all infants. -
These infants have routine bloodwork and coinciding with clinical blood draws, we will 
have 200 microliters placed in a capillary tube 
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Saliva sampling: After enrollment and once infant has started enteral morphine, so will 
definitely be included in study population, a buccal swab will be used to collect saliva 
from the infant’s cheek. The saliva will be stored at room temperature and batch 
shipped to Tufts University CTRC Core Laboratory for DNA extraction and SNP 
genotyping. The OPRM1, COMT and ABCB1 genes will be analyzed for a total of 
six single nucleotide polymorphisms. These genotype results will be used as 
clinical covariates in the pharmacodynamic modeling process. 
 
**After each enrolled infants, the collection times post dose that still require samples 
will be continually updated, and we will ensure that over the entire study population, 
we have an adequate number of samples at each timepoint. 
Morphine and morphine metabolite assay 
a. Samples will be centrifuged and serum will be frozen at -70C until mass spectrometry 
assay 
b. High performance liquid chromatography, mass spectrometry will be performed as 
described by Bouwmeester et al 137. This assay method is currently being reproduced at 
the JHH Applied Clinical Pharmacology laboratory. 
c. Morphine and morphine metabolite data will be kept in online database on secure 
server. 
Non-linear mixed effect modeling 
NONMEM software will be used for both the population pharmacokinetic and 
pharmacodynamic modeling. Based on prior IV morphine and metabolite modeling 
130,137, multiple covariates will be considered for the final model: 
-clinical covariates for PK model: All available data will be collected at the time of 
sample collection 
1. gestational age at birth and postnatal age; 2. birth weight and daily weight; 3. total 
bilirubin, serum creatinine; 4. positive pressure ventilation status (dichotomized, 0 for 
ventilated, 1 for extubated); 5. Treatment with known inducers of hepatic 
glucuronidation (phenobarbital, rifampicin, and carbamazepine)145 
-clinical covariates for PD model:1. length of narcotic therapy prior to NAS treatment; 2. 
cumulative exposure to morphine equivalents prior to narcotic exposure; 3. subcohort 
status (in utero vs ICU acquired NAS will be treated as a binary variable); 4. Co-
treatment with other CNS active medications (i.e. benzos, clonidine) 5. SNP category 
(major vs minor alleles) for OPRM1, COMT and ABCB1 genes. 
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Simulation of morphine doses for target NAS scores using PK/PD model 
NONMEM software will be used to simulate children which vary by the final model 
covariates to estimate dosing schemes which will result in target morphine 
concentrations and NAS scores.  
 
 
5. Inclusion/Exclusion Criteria 
Inclusion Criteria:  
a. In utero exposed cohort: >35 weeks gestational age at birth, exposed to 
heroine and/or methadone prenatally via maternal report, diagnosed with 
Neonatal Abstinence Syndrome via Modified Finnegan Withdrawal scores 
collected by newborn nursery RNs, treated with oral morphine for NAS. 
b. ICU exposed cohort: >35 weeks gestational age at birth, exposed to either 
fentanyl, morphine, or hydromorphone as part of medical care, diagnosed 
with Neonatal Abstinence Syndrome by clinical team and being treated with 
oral morphine for NAS. 
Exclusion Criteria: Infants with major chromosomal anomalies (trisomies), infant with 
CNS disease which would make NAS scoring inaccurate (hypoxic ischemic 
encephalopathy, stroke, major brain malformation) will be excluded. 
6. Drugs/ Substances/ Devices 
a. The rationale for choosing the drug and dose or for choosing the device to be used. 
b. Justification and safety information if FDA approved drugs will be administered for 
non-FDA approved indications or if doses or routes of administration or participant 
populations are changed. 
c. Justification and safety information if non-FDA approved drugs without an IND will 
be administered.  
 
There are no drugs/substances/devices which will be used as part of study protocol. 
Oral morphine is currently the standard of care for Neonatal Abstinence Syndrome and 
infants will only be eligible for the study if their primary clinical providers have 
diagnosed them with NAS and started oral morphine therapy. 
7. Study Statistics 
a. Primary outcome variable. 
b. Secondary outcome variables. 
c. Statistical plan including sample size justification and interim data analysis. 
d. Early stopping rules. 
 
This is a clinical pharmacology study, so typical outcome variables to do apply. We aim 
to accurately model with population estimates for clearance, volume of distribution and 
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to quantitatively estimate the interpatient variability around these estimates. We will 
consider multiple clinical covariates in the model (outlines in Study Design) in order to 
decrease this interpatient variability. The sample size of 40 infants per arm is based on 
prior publications investigating the clinical pharmacology of IV morphine and its 
metabolites, and oral morphine in older children with cancer. There will not be any early 
stoppage rules. 
8. Risks 
a. Medical risks, listing all procedures, their major and minor risks and expected 
frequency. 
b. Steps taken to minimize the risks. 
c. Plan for reporting unanticipated problems or study deviations. 
d. Legal risks such as the risks that would be associated with breach of confidentiality. 
e. Financial risks to the participants. 
 
Material to be collected as part of study procedures: 
Demographic information: From the infants chart, we will collect information about 
infant sex, race, basic medical history. 
Details of drug exposure: In the in utero exposed cohort, mothers will complete a verbal 
one page questionnaire at the time of consent which will identify substances used 
during the pregnancy, the duration and frequency of use. For the ICU exposed cohort, 
we will collect drug information from the patient chart which quantifies duration and 
cumulative exposure to opiate medications. 
NAS scores: The Modified Finnegan score is a non-invasive behavioral withdrawal score 
which is collected by the primary nurse every four hours while infant in being treated for 
NAS. These scores will be remotely extracted from the patient chart of an enrolled 
infant and stored in a database to be analyzed with the serum measurements of 
morphine. 
Peripheral blood draws: Each infant enrolled in the study will have maximum of4 
(depending on how long they are treated for NAS) heelstick blood draws (total of 50 
microliters or 3 drops of blood per draw). This equates to less than 1 ml/kg over the 
entire study period. Blood draws will never be more frequent that two times per week. 
These sample collections will be timed with routine bloodwork whenever possible. This 
is most likely to happen in the ICU population when even convalescing infants are 
ordered for bloodwork on a regular basis (usually once per week). With the exception of 
total biliurbin concentrations and blood for the state newborn screen, infants in the 
newborn nursery do not routinely undergo blood draws.  
Buccal saliva samples:There are no known risks of collecting buccal saliva from 
neonates. 
 
Risks to SubjectsThe collection of demographic information and NAS scores does not 
subject an infant to increased risk. Specifically for the newborn nursery cohort, the 
detailed maternal drug history could increase the risk of social sequelae for the mother 
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– infant dyad. The study information collected will be kept confidential and will be 
immediately de-identified after collection. In regards to the heelstick blood draw of 3 
drops - This is the standard method used to obtain blood from infants for routine 
hospital laboratory tests. The infant will experience some pain when the lancet goes 
into his/her heel. Other than this momentary pain, the discomfort of heel stick should 
be minimal. However, in about 10% of cases a small amount of bleeding under the skin 
will produce a bruise (hematoma). A small scar will form on the heel. The risk of local 
infection in this procedure is less than 1 in 1,000. Although venipuncture is an option for 
blood collection in neonates, given the extremely small volume required for the study, it 
seems that heelstick is the more reliable and least painful option. The specific SNP 
analysis that we are doing has limited clinical implications outside of the research realm 
at this point in time. The results of the SNP analysis will not be shared with the infant’s 
families and will be used solely for the purpose of the current research project. 
Minimizing risksMaternal drug use information collected at the time of consent will be 
kept separate from infant clinical chart after collection and will only be accessible to the 
primary investigator and co-investigators who need this information for later data 
analysis. Regarding heelstick blood draws, pain will be minimized with the following 
measure: prior heel warming, blanket swaddling, pacifier administration (with or 
without oral glucose solution), ambient light and noise reduction, and developmentally 
appropriate positioning. The nurses who are certified in heelstick technique will be the 
ones collecting the study samples. Of note, performing a POPULATION PK and PD 
analysis is a known method to limit number of samples required per subject and overall 
to estimate pharmacologic parameters. 
There are no anticipated financial risks to participants. 
9. Benefits 
a. Description of the probable benefits for the participant and for society. 
 
Risk benefit analysis The infants enrolled in the study will not experience any personal 
health benefit. Their medical management will not be altered by the results of the 
blood work or study recording of NAS scores. The blood draw is considered “minimal 
risk” as it is not outside of the realm of a procedure that many normal newborns have 
during a newborn nursery stay for purposes of measuring bilirubin or sending the 
legally mandated state newborn screen at 1-3 and 10-14 days of age. The minimal risk 
of blood draw is balanced by the overall population knowledge gained by the 
information gleaned from the study results, namely the clinical pharmacologic basis of 
morphine as treatment for NAS.  
10. Payment and Remuneration 
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a. Detail compensation for participants including possible total compensation, 
proposed bonus, and any proposed reductions or penalties for not completing 
the protocol. 
 
Families will be given a $20 Baby R Us gift card for their son/daughters participation in 
the study. The gift card would be transferred to the mother or father upon study 
consent (The gift card will only be given to the parent that signs the consent form). The 
parent consenting must complete and sign all payment and remuneration forms before 
the gift card can be transferred  
11. Costs 
a. Detail costs of study procedure(s) or drug (s) or substance(s) to participants and 
identify who will pay for them. 
The only cost associated with the study is measurement of morphine and morphine 
metabolites serum concentrations, and the DNA extraction and SNP analysis -  this will 
clearly be a research procedure and will be go to a non-clinical lab and be paid by the 
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RESEARCH PARTICIPANT INFORMED CONSENT AND PRIVACY 
AUTHORIZATION FORM 
 
Protocol Title:  Clinical Pharmacology of Oral Morphine for Neonatal Abstinence 
Syndrome 
Application No.: NA_00073443  
 
Sponsor: National Institute of Health (NIH) 
 
Principal Investigator: Estelle Gauda, MD  
                                         Neonatology Research Laboratories 
CMSC 6-104 
600 N. Wolfe Street 
Baltimore, Maryland 21287-3200 
egauda@jhmi.edu 
PHONE (410) 502-6794 
FAX (410) 614-8388   
  
1. What you should know about this study: 
 You are being asked to join a research study. 
 This consent form explains the research study and your part in the study.   
 Please read it carefully and take as much time as you need.  
 Please ask questions at any time about anything you do not understand.   
 Ask your study doctor or the study team to explain any words or information in this informed 
consent that you do not understand. 
 You are a volunteer.  If you join the study, you can change your mind later. You can decide not to 
take part or you can quit at any time. There will be no penalty or loss of benefits if you decide to quit 
the study.   
 During the study, we will tell you if we learn any new information that might affect whether you 
wish to continue to be in the study. 
 If you receive routine medical treatment (including medical or laboratory tests) in the study or if you 
are taking part in the study at the Clinical Research Unit, information about your research study 
participation will be included in your medical record, which is used throughout Johns Hopkins.   
Doctors outside of Johns Hopkins may not have access to this information.  You can ask the research 
team to send this information to any of your doctors. 
 When Johns Hopkins is used in this consent form, it includes The Johns Hopkins University, The 
Johns Hopkins Hospital, Johns Hopkins Bayview Medical Center, Howard County General Hospital, 
If you are using Epic for this study, fax a copy 
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Johns Hopkins Community Physicians, Suburban Hospital, Sibley Memorial Hospital and All 
Children’s Hospital.  
 The Johns Hopkins School of Medicine Institutional Review Board (IRB) sometimes reviews studies 
that are conducted at other institutions. These other institutions are solely responsible for conducting 
the study safely and according to the protocol that the Johns Hopkins IRB has approved. Information 
about how to contact the investigator at the institution that is responsible for the study is included in 
this form.  When another institution is conducting the study, the word “we” in this consent form may 
include both Johns Hopkins and the participating institution. 
 Biospecimens will be collected in this study.  Biospecimens may include any of the following: 
blood, tissue, saliva, urine, bone marrow, cells, etc.  Most biospecimens contain DNA, which is the 
genetic code for each person. 
 If children and adults can join this study, the word “you” in this consent form will refer to both you 
and your child. 
 During this study, you will not have access to certain medical information and test results collected 
for study purposes.  If an emergency occurs while you are in the study, medical information needed 
for your treatment can be made available to your study physician and other physicians who treat you.  
When the study is completed, all the information in your medical record will be available to you. 
 
2. Why is this research being done? 
This research is being done to better understand the treatment of infants with Neonatal Abstinence 
Syndrome (NAS). 
 
NAS is an illness which is the result of babies being exposed to opiate medications. Infants are exposed 
to opiates in two ways: 1. when the mother takes substances such as methadone or heroin while she is 
pregnant, or 2. when the infant is sick at birth and needs opiate medications for pain control and sedation 
as part of their care.  
 
Infants with NAS are watched closely and treated with oral morphine for their symptoms of withdrawal. 
The morphine is weaned (gradually lowered) until the infant no longer needs it. The goal is this study is 
to measure morphine and morphine metabolites (break-down products) in the infants’ blood and relate 
these levels to withdrawal symptoms. By understanding this connection between drug levels and 
symptoms, we hope to improve the dosing of morphine for future infants with Neonatal Abstinence 
Syndrome. 
 
All infants born at over 35 weeks gestation who are at risk for NAS or who have NAS are eligible for 
the study. Your infant will only be enrolled in the study if he/she requires oral morphine therapy for 
NAS as part of their regular care. 
 
Infants with Neonatal Abstinence Syndrome (NAS) may join.  
 
How many people will be in this study? 
 
About 40 infants from the full term newborn nursery and 40 infants from the Neonatal Intensive Care 
Unit will be in this study. 
 
3. What will happen if you join this study? 
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 If your infant was exposed to opiates during pregnancy: 
1. We will collect information from you about your drug use during pregnancy. This 
information is for study purposes only and will help us understand the way your infant 
responds to treatment for NAS. 
2. Your infant will have withdrawal scores measured every four hours by the nurse (this is 
routine patient care). As part of this research study, the withdrawal scores will be collected 
for the study records. 
3. If your infant has high withdrawal scores, they will be treated will oral morphine (this is 
routine patient care). 
4. No more than twice per week and as part of this research study, we will perform a heelstick 
to collect blood from the infant’s foot. This will be about eight drops of blood (less than 1/5 
of a teaspoon). The infant will never have more than a total of four blood draws while in the 
study. 
5. At the start of the study, we will use a swab to collect a small amount of saliva from inside 
your infant’s cheek. This saliva will be used to make a DNA sample and look at three genes 
that affect how a baby responds to morphine when being treated for NAS. The DNA will 
only be used to look at these three genes and no other genetic testing will be done. 
6. The results of the blood work (morphine and morphine metabolite levels) and the saliva 
(DNA results) are only used for the research study and the infant’s doctors will not know the 
results. 
 
 If your infant was exposed to opiates in the Intensive Care Unit: 
1. We will collect information on how much opiates the infant received. 
2. Your infant will have withdrawal scores measured every four hours by the nurse while he/she 
is being treated with oral morphine (this is routine patient care). As part of this research 
study, the withdrawal scores will be collected for the study records 
3. No more than twice per week and as part of this research study, we will perform a heelstick 
to collect blood from the infant’s foot. This will be about eight drops of blood (less than 1/5 
of a teaspoon). The infant will never have more than a total of four blood draws while in the 
study. 
4. At the start of the study, we will use a swab to collect a small amount of saliva from inside 
your infant’s cheek. This saliva will be used to make a DNA sample and look at three genes 
that affect how a baby responds to morphine when being treated for NAS. The DNA will 
only be used to look at these three genes and no other genetic testing will be done. 
5. The results of the blood work (morphine and morphine metabolite levels) and the saliva 
(DNA results) are only used for the research study and the infant’s doctors will not know the 
results. 
 
The Genetic Information Nondiscrimination Act (GINA) may help protect you from health insurance or 
employment discrimination based on genetic information.   
 
The law provides that health insurance companies and group health plans  
 may not ask for genetic information from this research and  
 may not use genetic information when making decision about eligibility or premiums 
 
The law will not stop health insurance companies from using genetic information to decide whether to 
pay claims. The law also will not help you get other types of insurance (such as: life, disability or long-
term care).  
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How long will you be in the study? 
Your infant will be in the study while he/she is being treated with oral morphine for NAS. This amount 
of time is different for every infant. 
 
You son/daughter will be in this study until they are discharged from the hospital.  
 
4. What are the risks or discomforts of the study? 
Heelstick blood draw: This is the standard method used to obtain blood from infants for routine 
hospital laboratory tests. The infant will experience some pain when the lancet goes into his/her heel. 
Other than this momentary pain, the discomfort of heel stick should be minimal. However, in about 10 
out of 100cases, a small amount of bleeding under the skin will produce a bruise. There is also an 
extremely low (less than 1 in 1,000) chance of bacteria from the skin entering the site and causing an 
infection. 
 
The study team will do everything in our power to decrease the pain associated with the heelstick. This 
includes swaddling the infant, giving a pacifier, and warming the heel prior to the stick so that the blood 
flows more freely.  
 
Oral swab for saliva sample to collect DNA: There are no known risks for collection of saliva with a 
swab. Despite the GINA protections and the best efforts of the research team, there may still be a risk if 
information about you were to become known to people outside of this study. 
 
Oral morphine: All infants in the study will be treated with oral morphine for Neonatal Abstinence 
Syndrome as part of their routine care. This medication may need to be increased or decreased based on 
your infant’s symptoms. It can be associated with constipation or itching (rarely) and in high doses, can 
cause decreases in a baby’s breathing or blood pressure. The morphine doses used for the treatment of 
NAS have not been related to these side effects. 
 
Loss of confidential information: There is the risk that information about your child may become 
known to people outside this study. To protect against this, the study team will keep all records with 
study information securely protected, but there is always a small risk that someone outside of the study 
could gain access to the study information. 
 
Despite the GINA protections and the best efforts of the research team, there may still be a risk if 
information about you were to become known to people outside of this study. 
 
Genetic information is unique to you, even without your name or other identifiers. For this reason, 
genetic information like DNA may be used to identify you and possibly your family members.  We have 
procedures (such as, labeling your biospecimens with a password protected code known only to select 
research staff) to prevent people working with your DNA from discovering if it belongs to you. 
However, there is the risk this can happen as new ways of tracing genetic information are being 
developed that may make re-identification of genetic information possible. 
 
There may be side effects and discomforts that are not yet known.   
 
5. Are there benefits to being in the study? 
 
There is no direct benefit to your infant from being in this study.  
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If your child takes part in this study, your child may help others in the future. The information we gain 
by studying the infants in this study will help us better take care of infants with Neonatal Abstinence 
Syndrome in the future. 
 
6. What are your options if you do not want to be in the study? 
If you decide not to allow your child to join this study, there is no change in the care or treatment of 
your infant.   You do not have to allow your child to join this study.  If your child does not take part in 
the study, your child’s care at Johns Hopkins will not be affected. 
 
7. Will it cost you anything to be in this study?   
No. The only study procedure that costs money is measuring morphine levels in the blood collected 
from your infant and this is paid for by the study team 
 
 
8. Will you be paid if you join this study? 
Once you have decided to enroll your infant, you will be given a $20 gift card to Babies R Us to buy 
supplies needed for your baby. Only one gift card will be given to the consenting parent for this study. 
 
You may be required to provide your social security number to be paid for taking part in this study. 
Federal tax law requires that you report your research payments when you file your taxes. If your total 
payments from Johns Hopkins exceed $600 per year, Johns Hopkins will report these payments to the 
Internal Revenue Service and you will receive a 1099-MISC form from us. 
 
9. Can you leave the study early? 
 You can agree to allow your child to be in the study now and change your mind later. 
 If you wish to end your child’s participation, please tell us right away. 
 Leaving this study early will not stop your child from getting regular medical care.  
 If your child leaves the study early, Johns Hopkins may use or give out your child’s health 
information that it already has if the information is needed for this study or any follow-up activities. 
 
 
10. How will your privacy be protected? 
 
We have rules to protect information about you.  Federal and state laws and the federal medical Privacy 
Rule also protect your privacy.  By signing this form you provide your permission, called your 
“authorization,” for the use and disclosure of information protected by the Privacy Rule. 
 
The research team working on the study will collect information about you.  This includes things learned 
from the procedures described in this consent form.  They may also collect other information including 
your name, address, date of birth, and information from your medical records. This could include 
information about HIV and genetic testing, or treatment for drug or alcohol abuse or mental health 
problems. 
 
The research team will know your identity and that you are in the research study.  Other people at Johns 
Hopkins, particularly your doctors, may also see or give out your information. We make this information 
available to your doctors for your safety.  If you think this study might affect your clinical care, please 
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People outside of Johns Hopkins may need to see or receive your information for this study.  Examples 
include government agencies (such as the Food and Drug Administration), safety monitors, other sites in 
the study and companies that sponsor the study. 
 
We cannot do this study without your authorization to use and give out your information.  You do not 
have to give us this authorization.  If you do not, then you may not join this study. 
 
We will use and disclose your information only as described in this form and in our Notice of Privacy 
Practices; however, people outside Johns Hopkins who receive your information may not be covered by 
this promise or by the federal Privacy Rule.  We try to make sure that everyone who needs to see your 
information keeps it confidential – but we cannot guarantee that your information will not be re-
disclosed. 
 
The use and disclosure of your information has no time limit. You may revoke (cancel) your permission 
to use and disclose your information at any time by notifying the Principal Investigator of this study by 
phone or in writing.  If you contact the Principal Investigator by phone, you must follow-up with a 
written request that includes the study number and your contact information.  The Principal 
Investigator’s name, address, phone and fax information are on page one of this consent form.  
 
If you do cancel your authorization to use and disclose your information, your part in this study will end 
and no further information about you will be collected. Your revocation (cancellation) would not affect 
information already collected in the study, or information we disclosed before you wrote to the Principal 
Investigator to cancel your authorization. 
 
11. Will the study require any of your other health care providers to share your health 
information with the researchers of this study? 
  
As a part of this study, the researchers may ask to see your health care records from your other health 
care providers.  This includes the results of any drug screens that you took during your pregnancy if 
your infant was exposed to opiates during pregnancy 
 
12. What treatment costs will be paid if you are injured in this study?  
 
Johns Hopkins does not have a program to pay you if you are hurt or have other bad results from being 
in the study.  However, medical care at Johns Hopkins is open to you as it is to all sick or injured people.   
 
 If you have health insurance:  The costs for any treatment or hospital care you receive as the result of 
a study-related injury will be billed to your health insurer. Any costs that are not paid for by your 
health insurer will be billed to you.  
 
 If you do not have health insurance:  You will be billed for the costs of any treatment or hospital care 
you receive as the result of a study-related injury. 
 
 By signing this form you will not give up any rights you have to seek compensation for injury.  
 
13. What other things should you know about this research study? 
a. What is the Institutional Review Board (IRB) and how does it protect you?  
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 and people from the local community.  
 
The IRB reviews human research studies. It protects the rights and welfare of the people taking part 
in those studies.  You may contact the IRB if you have questions about your rights as a participant or 
if you think you have not been treated fairly.  The IRB office number is 410-955-3008. You may 
also call this number for other questions, concerns or complaints about the research.  
 
b. What do you do if you have questions about the study?    
Call the principal investigator, Dr. Estelle B Gauda at 410-614-0151. If you wish, you may contact 
the principal investigator by letter or by fax.  The address and fax number are on page one of this 
consent form. If you cannot reach the principal investigator or wish to talk to someone else, call the 
IRB office at 410-955-3008.   
 
c. What should you do if you are injured or ill as a result of being in this study?  
If you think you are injured or ill because of this study, call Estelle B Gauda at 410-614-0151during 
regular office hours.  
 
If you have an urgent medical problem related to your taking part in this study, call Dr. Estelle B. 
Gauda at 410-614-0151during regular office hours and 410-748-3218 after hours and on weekends.  
  
 
d. What happens to Data and Biospecimens that are collected in the study?  
Johns Hopkins and our research partners work to understand and cure diseases. The biospecimens 
and/or data you provide are important to this effort. 
 
If you join this study, you should understand that you will not own your biospecimens or data, and 
should researchers use them to create a new product or idea, you will not benefit financially.  
 
With appropriate protections for privacy, Johns Hopkins may share your biospecimens and 
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14. What does your signature on this consent form mean? 
 Your signature on this form means that: 
 you understand the information given to you in this form  
 you accept the provisions in the form 
 you agree to join the study  
 You will not give up any legal rights by signing this consent form.  
 
WE WILL GIVE YOU A COPY OF THIS SIGNED AND DATED CONSENT FORM 
 
___________________________________________________________________________________________________________ 
Signature of Participant                                                                           (Print Name)                                                 Date/Time  
 
___________________________________________________________________________________________________________ 















Tamorah Lewis, MD 
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